Radiology Review Manual (Dahnert, Radiology Review Manual)

Authors: Dahnert, Wolfgang

Title: Radiology Review Manual, 6th Edition

Copyright 2007 Lippincott Williams & Wilkins

> Table of Contents > Chest

Chest

Differential Diagnosis of Chest Disorders

Pulmonary hemorrhage

CXR:

HRCT:

NUC:

Hemoptysis

Source: bronchial a. (90%), pulmonary a. ( recruitment of intercostal, inferior phrenic, internal mammary, subclavian aa.)
Rx: transcatheter particulate embolization of bronchial arteries using polyvinyl alcohol (PVA) + Gelfoam pledgets (effective in 70 95%, but recurrent bleeding in 20 30% of patients)

N.B.: search for artery of Adamkiewicz at vertebral level of T8 to L2 prior to embolization

DDx: hematemesis (containing food particles, dark blood, acid pH)

Aspiration

= intake of solid/liquid materials into the airways and lungs

Predisposing factors:

Substrate:

Pulmonary disease associated with cigarette smoking

Hypersensitivity to organic dusts

Drug-induced pulmonary damage

Histopathologic manifestations:

Disorders with hepatic and pulmonary manifestations

Pulmonary edema

Pathophysiology (Starling equation):

mnemonic: ABCDEFGHI - PRN

Atypical pulmonary edema = lung edema with an unusual radiologic appearance

Unusual form of pulmonary edema = lung edema from unusual causes

Increased Hydrostatic Pressure Edema

HRCT:

Radiographic Signs in Pressure Edema
PCWP [mm Hg] Findings
5 12 normal
12 17 cephalization of pulmonary vessels (only in chronic conditions)
17 20 Kerley lines, subpleural effusions
>25 alveolar flooding edema

Interstitial Pulmonary Edema

Cause: increase in mean transmural arterial pressure of 15 25 mm Hg

Alveolar Flooding Edema

Cause: increase in mean transmural arterial pressure of >25 mm Hg pressure-induced damage to alveolar epithelium

Bat-Wing Edema (in <10%)

Cause: rapidly developing severe cardiac failure (acute mitral insufficiency associated with papillary muscle rupture, massive MI, valve leaflet destruction by septic endocarditis) or renal failure

Asymmetric Distribution of Pressure Edema

Cause: morphologic lung changes in COPD, hemodynamics, patient position

Pulmonary Edema with Acute Asthma

Cause: air trapping maintains a positive intraalveolar pressure and thus decreases hydrostatic pressure gradient
Pathogenesis: associated with severity of M ller maneuver

Postobstructive Pulmonary Edema

Cause: following relief from an upper airway obstruction (impacted foreign body, laryngospasm, epiglottitis, strangulation)
Pathogenesis: (a) forced inspiration causes a high negative intrathoracic pressure (M ller maneuver) and increases venous return

(b) obstruction creates high positive intrathoracic pressure that impairs development of edema

Prognosis: resolution within 2 3 days

Edema with Pulmonary Embolism (<10%)

Cause: occlusion of pulmonary arterial bed causes redirection of blood flow and hypertension in uninvolved areas

Pulmonary Edema with Pulmonary Venoocclusive Disease

Cause: organized thrombi in small veins causes an increase in peripheral resistance and hydrostatic pressure

Permeability Edema

Heroin-induced Pulmonary Edema

Hx: overdose of opiates (almost exclusively with heroin, rarely with cocaine/ crack )
Frequency: 15% of cases of heroin overdose
Pathophysiology: depression of medullary respiratory center leading to hypoxia + acidosis

Cx:

Prognosis: 10% mortality rate

Pulmonary Edema following Administration of Cytokines

Frequency: in 75% of IL-2 therapy; in 20% of tumor necrosis factor therapy; in 25% of recombinant IL-2 therapy
Pathophysiology: permeability disruption of capillary endothelial cells

High-altitude Pulmonary Edema

Predisposed: young males after rapid ascent to >3,000 m
Cause: prolonged exposure to low partial oxygen atmospheric pressure
Pathophysiology: acute persistent hypoxia with endothelial leakage

Mixed Hydrostatic & Permeability Edema

Neurogenic Pulmonary Edema

Frequency: in up to 50% of severe brain trauma, subarachnoid hemorrhage, stroke, status epilepticus
Pathophysiology: modification in neurovegetative pathways causes sudden increase in pressure in pulmonary venules with reduced venous outflow

P.410

Dx: by exclusion
DDx: fluid overload, postextubation edema

Reperfusion Pulmonary Edema

Frequency: in up to 90 100%
Cause: pulmonary thrombendarterectomy for massive pulmonary embolism/for webs and segmental stenosis
Pathophysiology: rapid increase in blood flow + pressure

Reexpansion Pulmonary Edema

Cause: rapid reexpansion of a collapsed lung following evacuation of hydrothorax, hemothorax or pneumothorax
Pathophysiology: prolonged local hypoxic event, abrupt restoration of blood flow, sudden marked increase in intrapleural pressure, diffuse alveolar damage
Prognosis: 20% mortality

Pulmonary Edema due to Air Embolism

Cause: usually iatrogenic complication (neurosurgical procedure in sitting position, placement/manipulation of central venous line), rare in open/closed chest trauma
Pathophysiology: embolized air bubbles cause mechanical obstruction of pulmonary microvasculature

Postpneumonectomy Pulmonary Edema

Frequency: 2.5 5%; R > L pneumonectomy
Risk factors: excessive administration of fluid during surgery, transfusion of fresh frozen plasma, arrhythmia, marked postsurgical diuresis, low serum colloidal osmotic pressure
Pathophysiology: increased capillary hydrostatic pressure, altered capillary permeability
Prognosis: very high mortality rate

Pulmonary Edema after Lung Transplantation

Frequency: in up to 97% during first 3 days after surgery
Pathophysiology: tissue hypoxia, disruption of pulmonary lymphatic drainage, lung denervation

Unilateral Pulmonary Edema

Pulmonary Edema with Cardiomegaly

Pulmonary Edema without Cardiomegaly

mnemonic: U DOPA

Noncardiogenic Pulmonary Edema

mnemonic: The alphabet

Pneumonia

Classic pneumonia pattern:

  1. Lobar distribution:
  2. Bulging fissure:
  3. Pulmonary edema:
  4. Pneumatocele:
  5. Alveolar nodules:

Streptococcus pneumoniae

Klebsiella

Viral/Pneumocystis pneumonia

Staphylococcus

Varicella, bronchogenic spread of TB

Distribution:

Transmission:

Complications:

Bacterial Pneumonia

Lobar Pneumonia

DDx: Aspiration, pulmonary embolus

Lobular Pneumonia

Organism:

Atypical Bacterial Pneumonia

Organism:

Gram-negative Pneumonia

In 50% cause of nosocomial necrotizing pneumonias (including staphylococcal pneumonia)

Predisposed: elderly, debilitated, diabetes, alcoholism, COPD, malignancy, bronchitis, gram-positive pneumonia, treatment with antibiotics, respirator therapy

P.412

Organism:

Cx: (1) Exudate/empyema

(2) Bronchopleural fistula

Mycotic Infections of Lung

Growth: (a) mycelial form

(b) yeast form (depending on environment)

Source of contamination:

Viral Pneumonia

Pathophysiology:

Organism:

Path: necrosis of ciliated epithelial cells, goblet cells, bronchial mucous glands with frequent involvement of peribronchial tissues + interlobular septa
Age: most common cause of pneumonia in children under 5 years of age
Distribution: usually bilateral
Cx: (1) Bacterial superinfection (child becomes toxic after a week of sickness, peripheral consolidations + pleural effusion)

(2) Bronchiectasis

(3) Unilateral hyperlucent lung, bronchiolitis obliterans

Cavitating Pneumonia

other gram-negative organisms (eg, Klebsiella)

Cavitating Opportunistic Infections

DDx: Metastatic disease in carcinoma/Hodgkin lymphoma

Interstitial Pneumonia

Acute Interstitial Pneumonia

Organism: viruses, Mycoplasma, Pneumocystis

Chronic Interstitial Pneumonia

Modified Liebow classification:

P.413

added:

no longer included:

Recurrent Pneumonia in Childhood

Eosinophilic lung disease

Classification:

Neonatal lung disease

Parenchymal Lung Disease on 1st Day of Life

Air Leaks in Neonatal Chest

Mediastinal Shift & Abnormal Aeration in Neonate

Pulmonary Infiltrates in Neonate

mnemonic: I HEAR

Reticulogranular Densities in Neonate

Hyperinflation in Newborn

Hyperinflation in Child

mnemonic: BUMP FAD

Congenital Pulmonary Malformation

Abnormal Lung Patterns

Alveolar (Consolidative) Pattern

Classic appearance of airspace consolidation:

mnemonic: A2BC3

HRCT:

Diffuse airspace Disease

Air-space Opacification in Trauma

Localized Airspace Disease

mnemonic: 4P's & TAIL

Acute Alveolar Infiltrate

mnemonic: I 2 CHANGE FAST

Chronic Alveolar Infiltrate

mnemonic: STALLAG

CT Angiogram Sign

Interstitial lung disease

Path: stereotypical inflammatory response of alveolar wall to injury

(a) acute phase: fluid + inflammatory cells exude into alveolar space, mononuclear cells accumulate in edematous alveolar wall

(b) organizing phase: hyperplasia of type II pneumocytes attempt to regenerate alveolar epithelium, fibroblasts deposit collagen

(c) chronic stage: dense collagenous fibrous tissue remodels normal pulmonary architecture

Characterizing criteria:

Classification scheme:

Interstitial Lung Pattern on CXR

Signs of Acute Interstitial Disease

Signs of Chronic Interstitial Disease

Distribution of Interstitial Disease

mnemonic: SHIRT CAP

Chronic Diffuse Infiltrative Lung Disease

Prevalence: up to 15% of pulmonary conditions
Cause: >200 described disorders; in only 25 30% known/established etiology; 15 20 diseases comprise >90% of cases

CXR:

mnemonic: HIDE FACTS

Zonal Predilection of Chronic Diffuse Lung Disease

Chronic Diffuse Infiltrative Lung Disease of Upper Lung Zone

mnemonic: CASSET

CHRONIC DIFFUSE INFILTRATIVE LUNG DISEASE OF LOWER LUNG ZONE

mnemonic: BAD LASS RIF

Compartmental Predilection of Chronic Diffuse Lung Disease

Lung Volumes in Chronic Diffuse Lung Disease

CHRONIC DIFFUSE INFILTRATIVE LUNG DISEASE WITH NORMAL LUNG VOLUME

CHRONIC DIFFUSE INFILTRATIVE LUNG DISEASE WITH INCREASED LUNG VOLUME

mnemonic: ELECT

CHRONIC DIFFUSE INFILTRATIVE LUNG DISEASE WITH REDUCED LUNG VOLUME

due to fibrotic process

Pleural Disease in Chronic Diffuse Lung Disease

CHRONIC DIFFUSE INFILTRATIVE LUNG DISEASE WITH PNEUMOTHORAX

CHRONIC DIFFUSE INFILTRATIVE LUNG DISEASE WITH PLEURAL EFFUSION

CHRONIC DIFFUSE INFILTRATIVE LUNG DISEASE WITH PLEURAL THICKENING

Lymphadenopathy in Chronic Diffuse Lung Disease

Diffuse Fine Reticulations

Acute Diffuse Fine Reticulations

mnemonic: HELP

Chronic Diffuse Fine Reticulations

mnemonic: LIFE lines

Coarse Reticulations

Cx: (1) Intercurrent pneumothoraces

(2) Bronchogenic carcinoma = scar carcinoma

Cause:

DDx: bronchiectasis, cavitary metastases (rare)

Reticulations & Pleural Effusion

Reticulations & Hilar Adenopathy

Chronic Interstitial Disease Simulating Airspace Disease

Thoracic manifestations of Collagen vascular Disease
  Ankylosing Spondylitis Dermatomyositis Polymyositis Progressive Systemic Sclerosis Rheumatoid Arthritis Sj gren Syndrome Systemic Lupus Erythematosus (SLE)
Pulmonary fibrosis occasional common frequen frequent occasional occasional
Pleural disease frequent frequent
Diaphragm weakness frequent frequent
Aspiration pneumonia frequent frequent
Bronchiectasis occasional common
Apical fibrosis frequent
Bronchiolitis obliterans common
BOOP common common

Reticulonodular Lung Disease

mnemonic: Please Don't Eat Stale Tuna Fish Sandwiches Every Morning

Reticulonodular Pattern & Lower Lobe Predominance

mnemonic: CIA

Nodular Lung Disease

Macronodular Lung Disease

mnemonic: GAMMA WARPS

Micronodular Lung Disease

Diffuse Fine Nodular Disease & Miliary Nodules

FINE NODULAR DISEASE IN AFEBRILE PATIENT

P.421

FINE NODULAR DISEASE IN FEBRILE PATIENT

End-stage Lung Disease

Honeycomb Lung

mnemonic: SHIPS BOATS

Diffuse Lung Disease on HRCT

Patterns of Diffuse lung Disease on HRCT

Centrilobular Nodules

PERIBRONCHIAL/PERIBRONCHIOLAR NODULES

CENTRILOBULAR NODULES WITHOUT GROUND-GLASS OPACITIES

CENTRILOBULAR NODULES WITH GROUND-GLASS OPACITIES

Random Nodules

Thickened Bronchovascular, Interlobular Septal & Pleural Interstitium

Parenchymal Bands & Architectural Distortion

Smooth Thickening of Interstitium

HRCT of Bronchiolitis

[CT findings are nonspecific and must be interpreted in the appropriate clinical context]

Cause:

Pattern of Bronchiolar Disease

Tree-in-bud appearance

Histo: bronchiolar luminal impaction with mucus, pus or fluid

+ dilatation of distal bronchioles

+ bronchiolar wall thickening

+ peribronchiolar inflammation

(analogous to gloved finger appearance)

Mosaic Perfusion

Focal Air-trapping on HRCT

Ground-glass Attenuation

Large Symmetric Regions of Ground-glass Opacities

Focal Area of Ground-glass Attenuation

Ground-glass Opacities & Interlobular Septal Lines

Ground-glass Opacity & Reticular Change

Crazy-paving Pattern

Pulmonary nodule/mass

Solitary Nodule/Mass

Definition: any pulmonary/pleural sharply defined discrete nearly circular opacity
2 30 mm in diameter = nodule
>30 mm in diameter = mass (>90% prevalence of malignancy)

Incidence: 150,000 annually in USA on CXR

Early Lung Cancer Action Project:

233 noncalcified nodules in 1000 participants by CT;

P.425

2244 noncalcified nodules in 1000 of 1520 participants (Mayo Clinic) by CT

mnemonic: Big Solitary Pulmonary Masses Commonly Appear Hopeless And Lonely

Morphologic Evaluation of Solitary Pulmonary Nodule

Growth Rate Assessment of Indeterminate Solitary Pulmonary Nodule

General recommendation:

Best method (quite imprecise):

Doubling time (= time required to double in volume):

Disadvantage:

Clinical Assessment of Indeterminate Solitary Pulmonary Nodule

Management Strategies of Indeterminate Solitary Pulmonary Nodule

Probability of malignancy for indeterminate Solitary Pulmonary nodule
Characteristic/Feature Likelihood Ratio
spiculated margin 5.54
size >3 cm 5.23
>70 years of age 4.16
malignant growth rate 3.40
smoker 2.27
upper lobe location 1.22
size <10 mm 0.52
smooth margin 0.30
30 39 years of age 0.24
never smoked 0.19
20 29 years of age 0.05
benign calcification 0.01
benign growth rate 0.01

CT Halo Sign

Benign Lung Tumor

Lung Tumor in Childhood

Large Pulmonary Mass

mnemonic: CAT PIES

Cavitating Lung Nodule

Pulmonary Mass with Air Bronchogram

Air-crescent Sign

Shaggy Pulmonary nodule

mnemonic: Shaggy Sue Made Loving A Really Wild Fantasy Today

Multiple Pulmonary Nodules and Masses

mnemonic: SLAM DA PIG

Multiple Cavitating Nodules/Masses

Small Pulmonary Nodules

mnemonic: MALTS

Pulmonary Nodules & Pneumothorax

Pleura-based Lung Nodule

Intrathoracic Mass of Low Attenuation

Pneumoconiosis

= tissue reaction to the presence of an accumulation of dust in the lungs

Path:

Types:

Pneumoconiosis classification

according to ILO (International Labour Office)

Pneumoconiosis with Mass

Anthracosilicosis with:

Pulmonary calcifications

Multiple Pulmonary Calcifications

Calcified Pulmonary Nodules

mnemonic: HAM TV Station

Dense lung lesions

Opacification of Hemithorax

mnemonic: FAT CHANCE

Atelectasis

Signs:

Obstructive Atelectasis

Resorptive Atelectasis

Pathophysiology:

Cause: bronchiolar obstruction by

Nonobstructive Atelectasis

Pathophysiology:

Passive Atelectasis

Adhesive Atelectasis

Cicatrizing Atelectasis

Discoid Atelectasis

mnemonic: EPIC

Rounded Atelectasis

Cause: any type of pleural inflammatory reaction (asbestos as leading cause)

Pathomechanism:

thickening of visceral pleura with progressive wrinkling + folding of subpleural lung

Cause: posterobasal subpleural

Left Upper Lobe Collapse

DDx:

Multifocal Ill-defined Densities

Diffuse Infiltrates in Immunocompromised Cancer Patient

mnemonic: FOLD

Segmental & lobar Densities

Chronic infiltrates

Chronic Infiltrates in Childhood

mnemonic: ABC'S

Chronic Multifocal Ill-defined Opacities

Chronic Diffuse Confluent Opacities

Ill-defined Opacities with Holes

Recurrent Fleeting Infiltrates

Tubular Density

Mucoid Impaction

Perihilar Bat-wing Infiltrates

mnemonic: Please, Please, Please, Study Light, Don't Get All Uptight

Peripheral Reverse Bat-wing Infiltrates

mnemonic: REDS

Lucent Lung Lesions

Pulmonary Oligemia

Generalized Oligemia

= reduction in pulmonary blood volume

Regional Oligemia

Hyperlucent Lung

Bilateral Hyperlucent Lung

Unilateral Hyperlucent Lung

Localized Lucent Lung Defect

Lung Cavity

= tissue necrosis with bronchial drainage

Lung cyst

= round circumscribed space surrounded by an epithelial/fibrous wall of uniform/varied thickness containing air/liquid/semisolid/solid material

Multiple Lucent Lung Lesions

Multiple Lung Cavities

MULTIPLE THIN-WALLED CAVITIES

mnemonic: BITCH

Multiple Lung Cysts

Cystlike Pulmonary Lesions

mnemonic: C.C., I BAN WHIPS

Pleura

Pneumothorax

mnemonic: THE CHEST SET

Pleural effusion

Unilateral Pleural Effusion

The majority of massive unilateral pleural effusions are malignant (lymphoma, metastatic disease, primary lung cancer)!

Pleural Effusion & Large Cardiac Silhouette

Pleural Effusion & Hilar Enlargement

Pleural Effusion & Subsegmental Atelectasis

Pleural Effusion & Lobar Densities

Hemothorax

Solitary Pleural Mass

= density with incomplete margins and tapered superior + inferior borders

Multiple Pleural Densities

mnemonic: Mary Tyler Moore Likes Lemon

Pleural Thickening

mnemonic: TRINI

Apical Cap

Pleural calcification

mnemonic: TAFT

Mediastinum

Acute Mediastinal Widening

Mediastinal Shift

Pneumomediastinum

Frequency: in 1% of patients with pneumothorax

Source of air:

Pathophysiology:

DDx:

Spontaneous Pneumomediastinum

Age: neonates (0.05 1%), 2nd 3rd decade

Cause:

Traumatic Pneumomediastinum (rare)

Cause:

Mediastinal Fat

Low-attenuation Mediastinal Mass

Mediastinal Cyst

Frequency of Developmental Mediastinal Cyst

Mediastinal Mass

(excluding hyperplastic thymus glands, granulomas, lymphoma, metastases)

1. Neurogenic tumors (28%) : malignant in 16%
2. Teratoid lesions (19%) : malignant in 15%
3. Enterogenous cysts (16%)
4. Thymomas (13%) : malignant in 46%
5. Pericardial cysts (7%)

Thoracic Inlet Lesions

MASS RAIDER TRIANGLE

Anterior Mediastinal Mass

mnemonic: 4 T's

Middle Mediastinal Mass

mnemonic: HABIT5

Subcarinal Space Lesion

AORTICOPULMONARY WINDOW MASS

Widening of Paratracheal Space

Normal width: <5 mm

RETROCARDIAC SPACE OF HOLZKNECHT LESION

Posterior Mediastinal Mass

mnemonic: BELLMAN

Cardiophrenic-angle Mass

Right Cardiophrenic-angle Mass

Hypervascular Mediastinal Mass

Hilar mass

Eggshell Calcification of Nodes

Enlargement of azygos vein

Normal azygos vein (on upright CXR): 7 mm

Thymus

Thymic Mass

Diffuse Thymic Enlargement

Trachea amp; Bronchi

Tracheal Narrowing

Tracheal Tumor

Endobronchial Tumor

Bronchial Obstruction

mnemonic: MEATFACE

Mucoid Impaction

Bronchial Wall Thickening

Circumferential Tracheobronchial Wall Thickening

Signet-ring Sign

Broncholithiasis

Diaphragm

Bilateral Diaphragmatic Elevation

Unilateral Diaphragmatic Elevation

Chest wall

Chest Wall Lesions

Pancoast Syndrome

Cause: lung cancer (most common), breast cancer, multiple myeloma, metastases, lymphoma, mesothelioma

Lung Disease with Chest Wall Extension

Chest Wall Tumors in Children

Malignant Tumors of Chest Wall in Children

Benign Tumors of Chest Wall in Children

Bedside Chest Radiography

Benefit:

Unexpected findings: in 37 43 65%
Change in diagnostic approach/therapy: in 27%

P.450

Indications:

P.452

Function and Anatomy of Lung

Bronchopulmonary Anatomy

Airways

Embryology of Airways

first 5 weeks GA lung buds grow from ventral aspect of primitive foregut (from caudal end of laryngotracheal groove of primitive pharyngeal floor); pulmonary agenesis
5th week GA trachea + esophagus separate
5 16 weeks formation of tracheobronchial tree with bronchi, bronchioles, alveolar ducts, alveoli; bronchogenic cyst (= abnormal budding); pulmonary hypoplasia (= fewer than expected bronchi)
16 24 weeks dramatic increase in number + complexity of airspaces and blood vessels; small airways + reduction in number and size of acini

Anomalous Bronchial Division

Tracheal Bronchus

Accessory Cardiac Bronchus

P.453

Paracardiac Bronchus

Airway

Definition:

bronchus = cartilage in wall
bronchiole = absence of cartilage (after 6 to 12 divisions of segmental bronchus)
small airways = diameter <2 mm = small cartilaginous bronchi + membranous and respiratory bronchioles; account for 25% of airway resistance
large airways = diameter >2 mm; account for 75% of airway resistance

HRCT of normal lung (window level 700 HU, window width 1,000 1,500):

Acinus

[Primary Pulmonary Lobule]

Secondary Pulmonary Lobule

Size: 10 25 mm in diameter

P.454

Interstitial Anatomy

Lung Development

Surfactant

lung interstitium
Division Components
Axial bronchovascular sheaths, lymphatics
Middle (parenchymal) alveolar wall (interalveolar septum)
Peripheral pleura subpleural connective tissue, interlobular septa (enclosing pulmonary veins, lymphatics, walls of cortical alveoli)

Pulmonary Circulation

Lung function

Lung Volumes & Capacities

Terminal Airways within the Secondary Pulmonary lobule

Changes In Lung Volumes

P.457

Lung Volumes and Capacities

Flow Rates

Diffusing Capacity

Arterial Blood Gas Abnormalities

V/Q Inequality

Compliance

Mediastinum

Terminology: Spigelius (1578 1626): Quod per medium stat = what sits in the middle

Thymus

[thymos, Greek = warty excrescence, soul, spirit]

Embryogenesis:

Ectopic Thymus

Medical Devices on CXR

Cardiac Devices

Coronary Artery Bypass Surgery (CABG)

Coronary Artery Stent

Cardiac Pacemaker

Circulatory Assist Devices

Heart Valve Replacement

Vascular Devices

Central Venous Pressure Catheter

Implantable Access Devices

Peripheral Inserted Central Catheter (PICC)

P.459

Chest Disorders

Aids

Incidence: 2 million Americans are infected with HIV + 270,000 have AIDS (estimate in 1993); >50% develop pulmonary disease
Organism: human immunodeficiency virus (HIV) = human T-cell lymphotropic virus type III (HTLV III) = lymphadenopathy-associated virus (LAV)

Pathomechanism:

HIV retrovirus attaches to CD4 molecule on surface of T-helper lymphocytes + macrophages + microglial cells; after cellular invasion HIV genetic information is incorporated into cell's chromosomal DNA; virus remains dormant for weeks to years; after an unknown stimulus for viral replication CD4 lymphocytes are destroyed (normal range of 800 1,000 cells/mm3) and others become infected leading to impairment of the immune system; CD4 lymphocyte number and function decreases (at an approximate rate of 50 80 cells/year)

AIDS-defining illness related to CD4 T-lymphocyte count [cells/ L]:

<400 extrapulmonary Mycobacterium tuberculosis, Kaposi sarcoma
<200 Candida albicans (thrush, hairy leukoplakia), Histoplasma capsulatum, Cryptosporidium species, Pneumocystis carinii pneumonia, non-Hodgkin lymphoma
<150 cerebral toxoplasmosis
<100 Cytomegalovirus, Herpes simplex virus, Mycobacterium avium complex (intestinal CMV + MAI infection)
<50 AIDS-related lymphoma
Prognosis: median survival with CD4 lymphocyte count <50 cells/mm3 is 12 months
Transmission by: intimate sexual contact, exposure to contaminated blood/bloody body secretions

Groups at risk:

Clinical classification:

group I acute HIV infection with seroconversion
group II asymptomatic HIV infection
group III persistent generalized lymphadenopathy
group IV other HIV disease
subgroup A constitutional disease
subgroup B neurologic disease
subgroup C secondary infectious disease
subgroup D secondary cancers
subgroup E other conditions

AIDS-defining pulmonary conditions (CDC, 1987):

AIDS-related Complex (ARC)

Time interval: approximately 10 years between seroconversion + clinical AIDS

Adult Respiratory Distress Syndrome

Etiology:

Predisposed:

mnemonic: DICTIONARIES

Stages (often overlapping):

1st (exudative) stage

2nd (proliferative) stage

3rd (fibrotic) stage

CXR:

Alpha-1 Antitrypsin Deficiency

Source: alpha-1 antitrypsin (glycoprotein) is to >90% synthesized in hepatocytes + released into serum
Gene: codominant gene expression on chromosome 14 with >100 genetic variants of the protein; most severe hepatopulmonary manifestations result from homozygous Pizz phenotype
Action: proteolytic inhibitor of neutrophil elastase, trypsin, chymotrypsin, plasmin, thrombin, kallikrein, leukocytic + bacterial proteases; neutralizes circulating proteolytic enzymes

Mode of injury from deficiency:

Age: early age of onset (20 30 years); m:f = 1:1
Cx: hepatic cirrhosis (in homozygotic individuals)
Prognosis: 15 20-year decrease in longevity in smokers relative to nonsmokers

Alveolar Microlithiasis

Age peak: 30 50 years; begins in early life; has been identified in utero; m:f = 1:1; in 50% familial (restricted to siblings)

Prognosis:

DDx: mainline pulmonary granulomatosis = IV abuse of talc-containing drugs such as methadone (rarely as numerous + scarring + loss of volume)

Alveolar Proteinosis

Forms:

Pathophysiology:

Histo: alveoli filled with proteinaceous material (the ONLY pure airspace disease), normal interstitium
Age peak: 39 years (range, 2 70 years); M:F = 3:1

HRCT:

Cx: susceptible to pulmonary infections (secondary to poorly functioning macrophages + excellent culture medium): opportunistic pathogens (esp. Nocardia asteroides), other common respiratory pathogens

Prognosis:

Dx: bronchoalveolar lavage, transbronchial/open lung biopsy
Rx: bronchopulmonary lavage

DDx:

Amniotic Fluid Embolism

Pathogenesis: amniotic debris enters maternal circulation resulting in:

(1) pulmonary embolization

(2) anaphylactoid reaction

(3) DIC

P.463

Amyloidosis

Histo: protein (immunoglobulin)/polysaccharide complex; affinity for Congo red stain

Asbestos-Related Disease

[asbestos, Greek = inextinguishable = several fibrous silicate minerals sharing the property of heat resistance]

Substances:

Occupational exposure:

Pathophysiology:

Asbestos-related Pleural Disease

Pulmonary Asbestosis

Incidence: in 49 52% of industrial asbestos exposure
Latency period: 40 45 years; dose-effect relationship
Histo: interstitial fibrosis begins around respiratory bronchioles, then progresses to involve adjacent alveoli

Diagnostic criteria:

Location: lower posterior bases > apices
Site: most severe in subpleural zones (asbestos fibers concentrate beneath visceral pleura)

HRCT:

DDx: idiopathic pulmonary fibrosis

Atelectatic Asbestos Pseudotumor

Location: posteromedial/posterolateral basal region of lower lobes (most common); frequently bilateral

CT:

Asbestos-related Malignancy

Lung Cancer

Incidence: 180,000 new cases per year in united states; 20 25% of workers heavily exposed to asbestos

Occurrence related to:

Latency period: 25 35 years
Associated with: increased incidence of gastric carcinoma
Histo: bronchioloalveolar cell carcinoma (most common); bronchogenic carcinoma (adenocarcinoma + squamous cell)
Location: at lung base/in any location if associated with smoking

Malignant Mesothelioma

Incidence: 2,000 new cases per year in United States; 7,000-fold increase in incidence
Risk: 10% over lifetime of an asbestos worker; household members of asbestos worker; residents near asbestos mines and plants
Latency period: 20 40 years

Gastrointestinal Neoplasm

Incidence: 3-fold increase

Aspergillosis

Organism:

Occurrence:

Predisposed:

Cx: dissemination to heart, brain, kidney, GI tract, liver, thyroid, spleen

Noninvasive Aspergillosis

Histo: mycetoma = aspergilloma = fungus ball = masslike collection of intertwined hyphae matted together with fibrin, mucus, cellular debris colonizing a pulmonary cavity
Cx: life-threatening hemoptysis
Dx: transthoracic needle biopsy/bronchial washings

DDx of other organisms causing fungus ball:

Semiinvasive Aspergillosis

Dx: pathologic examination demonstrating local tissue invasion

Invasive Pulmonary Aspergillosis

Predisposed: most commonly in lymphoma/leukemia patients with prolonged granulocytopenia, after organ transplantation
Path: endobronchial fungal proliferation followed by transbronchial vascular invasion eventually causes widespread hemorrhage + thrombosis of pulmonary arterioles + ischemic tissue necrosis + systemic dissemination; fungus ball = devitalized sequestrum of lung infiltrated by fungi
Type of Aspergillosis relative to Immune Status

P.466

Prognosis: mortality rate of 50 90%
Dx: : biopsy showing branching hyphae at tissue examination; sputum culture positive in only 10%
Rx: amphotericin B

Allergic Bronchopulmonary Aspergillosis

Incidence: in 1 2% of patients with asthma;in 1 15% of patients with cystic fibrosis
Age: mostly young patients (begins in childhood); may be undiagnosed for 10 20 years

Pathophysiology:

Criteria:

Staging:

DDx: hypersensitivity pneumonitis or allergic asthma (no hyphae in sputum, normal levels of IgE + IgG to A. fumigatus), tuberculosis, lipoid pneumonia, L ffler syndrome, bronchogenic carcinoma

Pleural Aspergillosis

P.467

Aspiration of Solid Foreign Body

Aspiration Bronchiolitis

Predisposed: achalasia, Zenker diverticulum, esophageal carcinoma
Histo: resembling diffuse panbronchiolitis

CT:

Aspiration Pneumonia

Predisposing conditions:

Location: gravity-dependent portions of lung, posterior segments of upper lobes + lower lobes in bedridden patients, frequently bilateral, right middle + lower lobe with sparing of left lung is common

Acute Aspiration Pneumonia

Cause: gastric acid, food particles, anaerobic bacteria from GI tract provoke edema, hemorrhage, inflammatory cellular response, foreign-body reaction
Organism: gram-negative bacteria; Pseudomonas aeruginosa, Actinomyces israelii

Chronic Aspiration Pneumonia

Cause: repeated aspiration of foreign material from GI tract over long time/mineral oil (eg, in laxatives)
Associated with: Zenker diverticulum, esophageal stenosis, achalasia, TE fistula, neuromuscular disturbances in swallowing

upper Gi:

Mendelson Syndrome

Associated with: vomiting, gastroesophageal reflux, achalasia, hiatal hernia
Pathophysiology: acid rapidly disseminates throughout bronchial tree + lung parenchyma, incites a chemical pneumonitis within minutes; extent of injury from mild bronchiolitis to hemorrhagic pulmonary edema depends on pH + aspirated volume
Location: with patient in recumbent position: posterior segments of upper lobes + superior segments of lower lobes
Prognosis: 30% mortality with massive aspiration; >50% with initial shock, apnea, secondary pneumonia, or ARDS

Asthma

Path: bronchial plugging with large amounts of viscid tenacious mucus (eosinophils, charcot-Leyden crystals), edematous bronchial walls, hypertrophy of mucous glands + smooth muscle

ACUTE SIGNS:

CHRONIC CHANGES:

Cx:

Atypical Measles Pneumonia

Baritosis

Beh et Syndrome

Berylliosis

Substance: one of the lightest metals (atomic weight 9), marked heat resistance, great hardness, fatigue resistance, no corrosion
Occupational exposure: fluorescent light bulb factories
Histo: noncaseating granulomas within interstitium + along vessels + in bronchial submucosa

Acute Berylliosis (25%)

P.469

Chronic Berylliosis

Latent period: 5 15 years

Blastomycosis

Organism: soil-born saprophytic dimorphic fungus Blastomyces dermatitidis, mycelial phase in soil + round thick-walled yeast form with broad-based budding in mammals

Geographic distribution:

Age: several months of age to 80 years (peak between 25 and 50 years of age)

Mode of infection:

Predisposed: elderly, immunocompromised

Histo:

Dx: (1) Culture of organism

(2) Silver stain microscopy of tissues

Prognosis: spontaneous resolution of acute disease in up to 4 weeks; disease may reactivate for up to 3 years
Rx: (1) Amphotericin B IV: 8 10 weeks for noncavitary + 10 12 weeks for cavitary lesions

(2) Ketoconazole

DDx: other pneumonias (ie, bacterial, tuberculous, fungal), pseudolymphoma, malignant neoplasm (ie, alveolar cell carcinoma, lymphoma, Kaposi sarcoma)

Blunt Chest Trauma

Incidence: 100,000 hospital admissions/year (in USA)
Cause: high-speed motor vehicle accidents (70%)

Type of injury:

  1. Pneumothorax
  2. Lung contusion
  3. Rib fracture
  4. Hemothorax
  5. Flail chest
  6. Thoracic spine fracture
  7. Clavicle fracture
  8. Scapula fracture
  9. Sternal fracture
  10. Diaphragmatic injury
  11. Tracheobronchial tear
  12. Vascular injury
  13. Esophageal rupture

69%

67%

66%

28%

14%

13%

13%

8%

5%

5%

2%

2%

1%

Bone Marrow Transplantation

Cx: pulmonary complications in 40 60%

Neutropenic Phase Pulmonary Complications

Time: 2 3 weeks after transplantation

P.470

Early Phase Pulmonary Complications

Time: up to 100 days after transplantation

Late Phase Pulmonary Complications

Time: after 100 days post transplantation

Bronchial Adenoma

Path: arises from duct epithelium of bronchial mucous glands (predominant distribution of Kulchitsky cells at bifurcations of lobar bronchi)
Incidence: 6 10% of all primary lung tumors
Age: mean age of 35 45 years (range 12 60 years);90% occur <50 years of age;most common primary lung tumor under age 16;M:F = 1:1; Whites:Blacks = 25:1

Types:

mnemonic: CAMP
Carcinoid 90%
Adenoid cystic carcinoma = Cylindroma 6%
Mucoepidermoid carcinoma 3%
Pleomorphic carcinoma 1%
Location: most commonly near/at bifurcation of lobar/segmental bronchi; central:peripheral = 4:1
48% on right: RLL (20%), RML (10%), RUL (7%), main right bronchus (8%), intermediate bronchus (3%)
32% on left: LLL (13%), LUL (12%), main left bronchus (6%), lingular bronchus (1%)

CT:

Biopsy risky secondary to high vascularity of tumor
Prognosis: 95% 5-year survival rate, 75% 15-year survival rate after resection

Carcinoid

Incidence: 12 15% of all carcinoid tumors in the body; 1 4% of all bronchial neoplasms
Age peak: 5th decade (range of 2nd 9th decade); 4% occur in children + adolescents; m:f = 2:1; very uncommon in Blacks
Associated with: MEN 1 in <4% (almost all hormonally inactive)

Path:

Pathologic classification:

P.471

KCC I = classic carcinoid (least aggressive low-grade tumor)

= bronchial adenoma (misnomer)

= central location with endobronchial growth;

usually <2.5 cm in size + well-defined;

younger patient; m:f = 1:10; lymph node

metastases in 3%; rarely metastasize

KCC II = atypical carcinoid (25% of carcinoid tumors); central + peripheral location; mass usually >2.5 cm with well-defined margins; older patient; m:f = 3:1; lymph node metastases in 40 50%; metastases to brain, liver, bone (in 30%)
KCC III = small cell carcinoma (most aggressive); mediastinal lymphadenopathy; ill-defined tumor margins
Location: 58 90% central in lobar/segmental bronchi, 10 42% peripheral; located in submucosa; endobronchial/along bronchial wall/exobronchial

CT:

PET:

Malignant potential: low

Metastases:

Prognosis: 90% 10-year survival rate for classic carcinoids;

25 69% 5-year survival rate for atypical carcinoids

Rx: endobronchial resection, bronchial sleeve resection, segmentectomy, lobectomy, pneumonectomy

Cylindroma

Path: mixed serous + mucous glands; resembles salivary gland tumor

Histo:

Grade 1: tubular + cribriform; no solid subtype

entirely intraluminal

Grade 2: tubular + cribriform; <20% solid subtype

predominantly intraluminal

Grade 3: solid subtype >20%

predominantly extraluminal

Age peak: 4th 5th decade

Malignant potential:

Rx: tracheal resection + adjunctive radiotherapy
Prognosis: 8.3 years mean survival

Mucoepidermoid Carcinoma

Path: squamous cells + mucus-secreting columnar cells; resembles salivary gland tumor

Pleomorphic Adenoma

Bronchial Atresia

= local obliteration of proximal lumen of a segmental bronchus

Proposed causes:

Path: normal bronchial tree distal to obstruction patent and

containing mucus plugs; alveoli distal to obstruction airfilled

through collateral air drift

Associated with: lobar emphysema, cystic adenomatoid malformation
Location: apicoposterior segment of LUL (>>RUL/ML)
Rx: no treatment because mostly asymptomatic
DDx: Congenital lobar emphysema (no mucus plug)

Bronchiectasis

Etiology:

Classification:

Age: predominantly pediatric disease
Associated with: obliterative + inflammatory bronchiolitis (in 85%)
Location: posterior basal segments of lower lobes, bilateral (50%), middle lobe/lingula (10%), central bronchiectasis in bronchopulmonary aspergillosis

CXR (37% sensitive):

HRCT (87 97% sensitive, 93 100% specific):

Cx: frequent respiratory infections

DDx of CT appearance:

Bronchiolitis Obliterans

Etiology:

Path: submucosal and peribronchiolar fibrosis = irreversible fibrosis of small airway walls with narrowing/obliteration of airway lumina (respiratory bronchiole, alveolar duct, alveoli) by granulation tissue of immature fibroblastic plugs (Masson bodies)
Peak age: 40 60 years; M:F = 1:1

P.473

Rx: steroids may stop progression
DDx: (1) Bacterial/fungal pneumonia (response to antibiotics, positive cultures)

(2) Chronic eosinophilic pneumonia (young female, eosinophilia in 2/3)

(3) Usual interstitial pneumonia (irregular opacities, decreased lung volume)

Bronchiolitis obliterans with organizing pneumonia (BOOP)

Prevalence: 20 30% of all chronic infiltrative lung disease
Cause: postobstructive pneumonia, organizing adult respiratory distress syndrome, lung cancer, extrinsic allergic alveolitis, pulmonary manifestation of collagen vascular disease, pulmonary drug toxicity, silo filler disease, idiopathic (50%)
Path: granulation tissue polyps filling the lumina of alveolar ducts and respiratory bronchioles (bronchiolitis obliterans) + variable degree of infiltration of interstitium and alveoli with macrophages (organizing pneumonia)
Histo: plugs of immature fibroblasts (Masson bodies) covered with low cuboidal epithelium, which may spread through collateral air drift pathways
Age: 40 70 years; M:F = 1:1
Location: mainly mid + lower lung zones; often subpleural (50%) and peribronchiolar distribution (30 50%)
Rx: improvement with corticosteroid therapy (in 84% of patients with idiopathic form)
Prognosis: persistent abnormalities (30%); 10% mortality due to progressive/recurrent disease
Dx: tissue examination from open lung biopsy

Bronchioloalveolar Carcinoma

Incidence: 1.5 6% of all primary lung cancers (increasing incidence to? 20 25%)
Etiology: development from type ii alveolar epithelial cells
Age: 40 70 years; m:f = 1:1 (strikingly high in women)
Path: peripheral neoplasm arising beyond a recognizable bronchus with tendency to spread locally using lung structure as a stroma (= lepedic growth)
Histo: subtype of well-differentiated adenocarcinoma; cuboidal/columnar cells grow along alveolar walls + septa without disrupting the lung architecture or pulmonary interstitium (serving as scaffolding for tumor growth)

Subtypes:

Risk factors: localized pulmonary fibrosis (tuberculous scarring, pulmonary infarct) in 27%, diffuse fibrotic disease (scleroderma), previous exogenous lipid pneumonia
Location: peripherally, beyond a recognizable bronchus
Spread: tracheobronchial dissemination = cells detach from primary tumor + attach to alveolar septa elsewhere in ipsi-/contralateral lung; lymphogenous + hematogenous dissemination
Metastases: involving almost any organ (in 50 60%); 33% of skeletal metastases are osteoblastic
Prognosis: worse with extensive consolidation/multifocal/bilateral disease; death within 3 years with diffuse disease

Bronchocentric Granulomatosis

Age: 4th 7th decade
Path: thick-walled ectatic bronchi + bronchioles containing viscous material of mucopurulent/caseous character
Histo: necrotizing granulomas surrounding small airways; pulmonary arteritis as a secondary phenomenon

(1) large masses of eosinophils in necrotic zones, associated with endobronchial mucus plugs, eosinophilic pneumonia, Charcot-Leyden crystals, fungal hyphae in granulomas (with asthma)

(2) polymorphonuclear cell infiltrate in necrotic zones (without asthma)

Location: unilateral (75%); upper lobe predominance
Rx: corticosteroid therapy

Bronchogenic Carcinoma

Prevalence: in 1991 161,000 new cases; 143,000 deaths
Age at diagnosis: 55 60 years (range 40 80 years); M:F = 1.4:1

Risk factors:

Types:

Location:

Presentation:

Cx:

Prognosis: mean survival time <6 months; 10 13 15% overall 5-year survival; survival at 40 months: squamous cell 30% > large cell 16% > adenocarcinoma 15% > oat cell 1%

Rx:

Staging for small cell lung cancer:

Prognosis: 7 11 months median survival; 15 20% 2-year disease-free survival rate

MULTIPLE PRIMARY LUNG CANCERS

Incidence: 0.72 3.5%; in 1/3 synchronous, in 2/3 metachronous
Dx: biopsy mandatory for proper therapy because the tumor may have a different cell type

PARANEOPLASTIC MANIFESTATIONS

International System for Staging of Lung Cancer

Stage Description
IA T1 tumor in the absence of nodal/extrathoracic metastases
IB T2 tumor in the absence of nodal/extrathoracic metastases
IIA T1n1m0
IIB T2n1m0 + T3n0m0
IIIA T3 other than T3n0m0/n2
IIIB T4/n3 disease
IV metastatic disease

TNM Staging of Lung Cancer

Stage Description
T1 <3 cm in diameter, surrounded by lung/visceral pleura
T2 3 cm in diameter/invasion of visceral pleura/lobar atelectasis/obstructive pneumonitis/at least 2 cm from carina
T3 tumor of any size; less than 2 cm from carina/invasion of parietal pleura, chest wall, diaphragm, mediastinal pleura, pericardium; pleural effusion; satellite nodule in same lobe
T4 invasion of heart, great vessels, trachea, esophagus, vertebral body, carina/malignant pleural effusion
N1 peribronchial/ipsilateral hilar nodes
N2 ipsilateral mediastinal nodes
N3 contralateral hilar/mediastinal nodes; scalene/supraclavicular nodes

SPREAD

DISTANT METASTASES

Likelihood: small cell > adeno > large cell > squamous
Location: vertebrae (70%), pelvis (40%), femora (25%)

Bronchogenic Cyst

Incidence: most common intrathoracic foregut cyst (54 63% in surgical series)
Histo: thin-walled cyst filled with mucoid material, lined with columnar respiratory epithelium, mucous glands, cartilage, elastic tissue, smooth muscle

P.478

Mediastinal Bronchogenic Cyst (86%)

Associated with: spinal abnormalities

M:F = 1:1

Location: pericarinal (52%), paratracheal (19%), esophageal wall (14%), retrocardiac (9%); usually on right

Intrapulmonary Bronchogenic Cyst (14%)

Location: lower:upper lobe = 2:1; usually medial third
DDx: solitary pulmonary nodule, cavitated neoplasm, cavitated pneumonia, lung abscess

Bronchopulmonary Dysplasia

Cause: oxygen toxicity (lung damage by oxygen radicals) + barotrauma (bronchopulmonary injury from assisted ventilation)
Pathogenesis: hypoxia + oxygen toxicity
Path: loss of ciliated cells + necrosis of bronchiolar mucosa
Path: hyaline membranes, eosinophilic exudate, squamous metaplasia, interstitial edema
Associated with: congestive failure from PDA
Path: fewer hyaline membranes, persistent injury of alveolar epithelium, exudation of macrophages
Path: septal wall thickening, dilated + tortuous lymphatics

CT:

Prognosis: 40% mortality if not resolved by 1 month

Cx:

Rx : supportive
Prognosis: (1) Complete clearing over months/years (1/3) (2) Retained linear densities in upper lobe emphysema (29%)

DDx:

Bronchopleural Fistula

Cause:

HRCT:

Dx: (1) Introduction of methylene blue into pleural space, in 65% dye appears in sputum (2) Sinography (3) Bronchography
Rx: tube thoracostomy, open drainage, decortication, thoracoplasty, muscle-pedicle closure, transbronchial occlusions

Bronchopulmonary Sequestration

Incidence: 0.15 6.4% of all congenital pulmonary malformations; 1.1 1.8% of all pulmonary resections
DDx: bronchiectasis, lung abscess, empyema, bronchial atresia, congenital lobar emphysema, cystic adenomatoid malformation, intrapulmonary bronchogenic cyst, Swyer-James syndrome, pneumonia, arteriovenous fistula, primary/metastatic neoplasm, hernia of Bochdalek

Intralobar Sequestration (75 86%)

Etiology: controversial

(1) probably acquired in majority of patients

(2) early appearance of congenital accessory tracheobronchial bud leads to incorporation within one pleural investment

Path: chronic inflammation fibrosis: multiple irregular cordlike adhesions to mediastinum, diaphragm, parietal pleura; multiple cysts filled with fluid/thick gelatinous/purulent material; vascular sclerosis
Age at presentation: adulthood (50% >20 years); M:F = 1:1

Associated with congenital anomalies in 6 12%:

Location: posterobasal segments, rarely upper lung/within fissure; L:R = 3:2

CXR:

Bronchogram:

Angio:

CT:

OB-US:

Cx: massive spontaneous nontraumatic pleural hemorrhage, chronic inflammation, fibrosis
DDx of mass: neurogenic tumor, lateral thoracic meningocele, extramedullary hematopoiesis, pleural tumor
DDx of cavity: lung abscess, necrotizing pneumonia, fungal/mycobacterial pneumonia, cavitating neoplasm, empyema
DDx of cysts: pulmonary abscess, empyema, bronchiectasis, emphysema, bronchogenic foregut cyst, pericardial cyst, eventration of diaphragm, congenital cystic malformation

Extralobar Sequestration (14 25%)

Etiology: development of an anomalous accessory/supernumerary tracheobronchial foregut bud
Path: single ovoid/rounded/pyramidal airless lesion between 0.5 and 15 cm (generally 3 to 6 cm) in size
Histo: resembles normal lung with diffuse dilatation of bronchioles + alveolar ducts + alveoli; dilatation of subpleural + peribronchiolar lymph vessels; covered by mesothelial layer overlying fibrous connective tissue; congenital cystic adenomatoid malformation type ii is present in 15 25%
Incidence: 0.5 6% of all congenital lung lesions
Age: neonatal presentation; 61% within first 6 months of life; occasionally in utero; m:f = 4:1

Associated with congenital anomalies in 15 65%:

Bronchopulmonary Sequestrations
  Intralobar Extralobar
Prevalence 75% 25%
Venous drainage pulmonary veins systemic veins
symptomatic adulthood first 6 months
Etiology acquired developmental
congen. anomalies 15% 50%
Location: L:r = 4:1; typically within pleural space in posterior costodiaphragmatic sulcus between diaphragm + lower lobe (63 77%); mediastinum; within pericardium; within/below diaphragm (5 15%)

DDx for chest lesion:

DDx for infradiaphragmatic lesion:

Cx: infection (in cases of communication with bronchus/GI tract)
Rx: resection (delineation of vascular supply helpful)
Prognosis: favorable (worse if pulmonary hypoplasia present); decreases in size/disappears in up to 65% before birth

P.481

Esophageal/Gastric Lung

Age: infancy (as it is symptomatic)

Candidiasis

Organism: ubiquitous human saprophyte (Candida albicans most commonly) characterized by blastospheres (yeasts) admixed with hyphae/pseudohyphae (conventional stains)
At risk: patient with lymphoreticular malignancy

Entry:

Cardiopulmonary Schistosomiasis

Organism: Schistosoma mansoni (endemic in Middle East, Africa, Atlantic coast of South America, Caribbean; S. japonicum and S. haematobium (less commonly)
At risk: >5 years of continuous ova secretion
Prerequisite: portal hypertension with periportal hepatic fibrosis
Cycle: eggs travel as emboli via portosystemic collateral pathways to lodge in pulmonary muscular arteries and arterioles (50 150 m in diameter)
Pathogenesis: trapped eggs are antigenic and incite an obliterative endarteritis (due to delayed host hypersensitivity)
Path: intra- and perivascular granulomas, intimal hyperplasia, medial hypertrophy, concentric collagen deposition and fibrosis of vessel walls; localized alveolitis with eosinophilic infiltration; pulmonary infarction
Age: 25 35 (range of 1 93) years

CXR:

HRCT:

Cx: cor pulmonale (2 33%)
Rx: praziquantel, oxamniquine

Castleman Disease

Histo:

Localized/Unicentric Angiofollicular Lymph Node Hyperplasia

Cause: chronic viral antigenic stimulation with reactive lymphoid hyperplasia/developmental growth disturbance of lymphoid tissue
Age: all age groups (peak in 4th decade); M:F = 1:4
Histo: mostly hyaline-vascular cell type
Location: middle mediastinum + hila, cervical lymph nodes, mesenteric + retroperitoneal lymph nodes

Morphologic types:

Size: up to 16 cm in diameter

CT:

MR:

Angio:

DDx: indistinguishable from lymphoma
Prognosis: treatment ~100% curative
Rx:
(1) Complete surgical resection (2) Radiation + steroid therapy

Disseminated/Generalized/Multicentric Angiofollicular Lymph Node Hyperplasia

Cause: disordered immunoregulation with polyclonal plasma cells from viral infection with uncontrolled B-cell proliferation + interleukin-6 dysregulation
Mean age: 40 60 years; M:F = 2:1
Histo: mostly plasma cell type (66%) with infiltration of nodes by sheets of mature plasma cells

Associated with:

Rx: surgical resection, irradiation, systemic chemotherapy + corticosteroids
Prognosis: mean survival of 24 33 months

Chemical pneumonitis

Carbamates

Paraquat

Exposure: often intentional ingestion
Pathophysiology: rapid accumulation in lungs with production of superoxide radicals damaging pulmonary cells

CXR (wide radiographic variation):

HRCT:

Hydrogen Sulfide

Industries: coal mines, tanneries, petroleum manufacturing plants, geothermal power plants, aircraft factories, sewer works, rubber works
Effect: toxic for respiratory (large quantities cause inhibition of medullary respiratory center) + neurologic systems

Ammonia

Industries: production of explosives, petroleum, agricultural fertilizer, plastics
Prognosis: complete recovery; bronchiectasis + bronchiolitis obliterans may develop

Hydrocarbon

Exposure: ingestion/aspiration (eg, accidental poisoning in children; fire-eating performers)
Path: (a) acute phase: intraalveolar, intrabronchial, peribronchial, interstitial accumulation of inflammatory cells + edema

(b) chronic phase (1 2 weeks after initial onset): proliferative bronchiolitis, parenchymal fibrosis, pneumatocele formation

Mercury

Exposure: inhalation of mercury vapor
Industries: electrolysis, manufacture of thermometers, cleaning of boilers, smelting silver from dental amalgam containing mercury
Pathophysiology: acute chemical bronchiolitis + pneumonitis followed by diffuse alveolar damage with hyaline membrane formation

P.483

Prognosis: acute inhalation poisoning usually fatal

Chronic Eosinophilic Pneumonia

Etiology: unknown
Age: middle-age; M < F
Rx: dramatic response to steroid therapy (within 3 10 days)

Chronic Mediastinitis

Etiology:

Mediastinal Granuloma

Cause: primary lymph node infection (commonly tuberculosis/histoplasmosis)
Histo: thin fibrous capsule surrounding granulomatous lesion
DDx: fibrosing mediastinitis (infiltrative, rare)

Fibrosing Mediastinitis

Cause: abnormal host immune response to Histoplasma capsulatum antigen (organisms recovered in 50%); autoimmune disease, methysergide-induced
May be associated with: retroperitoneal fibrosis, orbital pseudotumor, sclerosing thyroiditis, riedel struma
Path: ill-defined soft-tissue mass with minimal/no apparent granulomatous foci
Histo: abundant paucicellular fibrous tissue infiltrating + obliterating adipose tissue
Age: 2nd 5th decade of life; m = f
Location: middle mediastinum (subcarinal + paratracheal regions) and hila
Site: right > left side of mediastinum

CXR:

UGI:

CT:

MR:

NUC:

Angio (with therapeutic intent):

Cx: (1) Compression of SVC (64%) + pulmonary veins (4%)

(2) Chronic obstructive pneumonia (narrowing of trachea/central bronchi) in 5%

(3) Esophageal stenosis (3%)

(4) Pulmonary infarcts + fibrosis (narrowing of pulmonary artery)

(5) Prominent intercostal arteries (narrowing of pulmonary artery)

Rx: resection, ketoconazole, steroid therapy (limited success)
DDx: (1) Bronchogenic carcinoma

(2) Lymphoma

(3) Metastatic carcinoma

(4) Mediastinal sarcoma

P.484

Churg-Strauss Syndrome

= ALLERGIC ANGITIS AND GRANULOMATOSIS

= variant of polyarteritis nodosa in asthmatic patients

Etiology: ? hypersensitivity response to an inhaled agent
Age: 20 40 (mean 28) years; M:F = 1:1

CLASSIC TRIAD:

Path:

Prognosis: 85% 5-year survival; death from cardiac/intraabdominal complications, cerebral hemorrhage, renal failure, status asthmaticus
Rx: corticosteroids, cyclophosphamide

Chylothorax

Route of thoracic duct:

Origin: arises from cisterna chyli anterior to L1 2 (10 15 mm in diameter and 5 7 cm long)
Course: enters thorax through aortic hiatus; ascends in right prevertebral location (between azygos vein + descending aorta); swings to left at T4 6 posterior to esophagus; ascends for a short distance along right of aorta; crosses behind aortic arch; runs ventrally at T3 between left common carotid artery + left subclavian artery
Termination: 3 5 cm above clavicle at venous angle (= junction of left subclavian + internal jugular veins)
Variation: two (33%) or more (in up to 50%) main ducts each consisting of up to 8 separate channels

Etiology:

Age: in full-term infants; may be present in utero; M:F = 2:1
Incidence: 1:10,000 deliveries

May be associated with:

Cx: (1) Pulmonary hypoplasia

(2) Hydrops (congestive heart failure secondary to impaired venous return)

Rx: (1) Thoracentesis (leading to loss of calories, lymphocytopenia, hypogammaglobulinemia)

(2) Total parenteral nutrition

(3) Thoracic duct ligation (if drainage exceeds 1,500 mL/day for adults or 100 mL/yr-age/day for children >5 years of age; drainage >14 days)

(4) Pleuroperitoneal shunt; tetracycline pleurodesis; mediastinal radiation; intrapleural fibrin glue; pleurectomy

Coal Worker's Pneumoconiosis

Simple CWP

Histo: development of reticulin fibers associated with bronchiolar dilatation (focal emphysema) + bronchiolar artery stenosis (decreased capillary perfusion)
Cx: (1) Chronic obstructive bronchitis

(2) Focal emphysema

(3) Cor pulmonale

Coccidioidomycosis

Organism: dimorphic soil fungus Coccidioides immitis; arthrospores in desert soil spread by wind aerosolized in dry dust; highly infectious

Geographic distribution:

endemic in southwest desert of USA (San Joaquin Valley, central southern Arizona, western Texas, southern New Mexico) + northern Mexico + in parts of Central + South America; similar to histoplasmosis

Mode of infection: deposited in alveoli after inhalation + maturation into large thick-walled spherules with release of hundreds of endospores
Dx: (1) Culture of organism

(2) Spherules in pathologic material (demonstrated with Gomori-methenamine silver stain)

(3) Positive skin test

(4) Complement fixation titer

Primary Coccidioidomycosis

Chronic Respiratory Coccidioidomycosis

Prevalence: 5% of infected patients

Disseminated Coccidioidomycosis (in 1%)

Congenital Lobar Emphysema

Etiology:

Associated with: CHD in 15% (PDA, VSD)
Location: LUL (42 43%), RML (32 35%), RUL (20%), two lobes (5%)
Mortality: 10%
Rx: surgical resection

Congenital Lymphangiectasia

Primary Pulmonary Lymphangiectasia (2/3)

Path: subpleural cysts, ectatic tortuous lymph channels in pleura, interlobular septa + along bronchoarterial bundles; NO obstruction
Age: usually manifest at birth; 50% stillborn; M = F
May be associated with: total anomalous pulmonary venous return, hypoplastic left heart, Noonan syndrome
Site: diffuse involvement of both lungs, occasionally only in one/two lobes (with good prognosis)
Prognosis: in diffuse form invariably fatal at <2 months of age

Generalized Lymphangiectasia

Age: children, young adults
Location: widespread visceral + skeletal involvement

Localized Lymphangioma

Histo: collection of dilated + proliferated lymph vessels (? hamartoma/benign neoplasm/focal sequestration of ectatic lymph tissue)
Age: first 3 years of life; m = f
Location: neck (80%), mediastinum, axilla, extremity
Prognosis: propensity for local recurrence
DDx: hemangioma

Secondary Lymphangiectasia

secondary to elevated pulmonary venous pressure in ChD (TAPVR)

Congenital Pulmonary Venolobar Syndrome

P.487

Associated with:

Location: right-sided predominance; M:F = 1.0:1.4
DDx: meandering pulmonary vein, dextrocardia, hypoplastic lung, Swyer-James syndrome

Costochondritis

Incidence: increased with IV drug abuse
Agents: Staphylococcus epidermidis, Streptococcus pneumoniae, Candida albicans, Aspergillus

CT:

Rx: surgical excision

Cryptococcosis

Organism: encapsulated unimorphic yeastlike fungus Cryptococcus neoformans; spherical single-budding yeast cell with thick capsule, stains with India ink; often in soil contaminated with pigeon excreta
Histo: granulomatous lesion with caseous necrotic center
Predisposed: opportunistic invader in diabetics + immunocompromised patients

Cystic Adenomatoid Malformation

Incidence: 25% of congenital lung disorders;

95% of congenital cystic lung lesions

Cause: arrest of normal bronchoalveolar differentiation between 5th 7th week of gestation with overgrowth of terminal bronchioles
Path: proliferation of bronchial structures at the expense of alveolar saccular development, modified by intercommunicating cysts of various size (adenomatoid overgrowth of terminal bronchioles, proliferation of smooth muscle in cyst wall, absence of cartilage)
TYPE I (50%):
Histo: single/multiple large cyst(s) >20 mm lined by ciliated pseudostratified columnar epithelium, mucus-producing cells in 1/3
Prognosis: excellent following resection
TYPE II (40%):
Histo: multiple cysts 5 12 mm lined by ciliated cuboidal/columnar epithelium
Prognosis: poor secondary to associated abnormalities
TYPE III (10%):
Histo: solitary large bulky firm mass of bronchuslike structures lined by ciliated cuboidal epithelium with 3 5-mm small microcysts
Prognosis: poor secondary to pulmonary hypoplasia/hydrops

In 25% associated with:

P.488

Age of detection: children, neonates, fetus; M:F = 1:1
Location: equal frequency in all lobes (middle lobe rarely affected); more than one lobe involved in 20%; mostly unilateral without side preference

CXR:

CT:

OB-US:

Risk of recurrence: none
Cx: ipsi-/bilateral pulmonary hypoplasia
Prognosis: 50% premature, 25% stillborn
DDx: (1) Congenital lobar emphysema

(2) Diaphragmatic hernia

(3) Bronchogenic cyst (small solitary cyst near midline)

(4) Neurenteric cyst

(5) Bronchial atresia

(6) Bronchopulmonary sequestration (less frequently associated with polyhydramnios/hydrops)

(7) Mediastinal/pericardial teratoma

Cystic Fibrosis

Incidence: 1:2,000 1:2,500 livebirths; almost exclusively in Caucasians (5% carry a CF mutant gene allele); unusual in Blacks (1:17,000), Orientals, Polynesians

The most common inherited disease among Caucasian Americans!

Cause: cystic fibrosis transmembrane regulator gene (CFTR) on long arm of chromosome 7 builds a defective ion transport protein for an epithelial chloride channel; abnormal transmembrane conductance for Cl decreases osmotic forces and thus luminal water; >230 different gene mutations (in 70% F508)

Screening (for 6 most common mutations of CF gene):

carrier detection rate of 85% of Northern Europeans, 90% of Ashkenazi Jews, 50% of American Blacks

Age at diagnosis: 1st year of life (70%), by age 4 years (80%), by age 12 years (90%); mean age of 2.9 years; M:F = 1:1
Location: predilection for apical + posterior segments of upper lobes

CT:

NUC:

Cx: (1) Pneumothorax (rupture of bulla/bleb), common + recurrent

(2) Hemoptysis (parasitized bronchial arteries connect to pulmonary arteries + veins resulting in AV fistulae)

(3) Cor pulmonale

(4) Hypertrophic pulmonary osteoarthropathy (rare)

Cause of death: massive mucous plugging (95%)
Rx: intratracheal instillation of aerosolized adenoviral + liposomal vector-CFTR gene preparations

Diaphragmatic Hernia

Congenital diaphragmatic Hernia

P.490

Embryology: ventral component of diaphragm formed by septum transversum during 3rd 5th week GA; gradually extends posteriorly to envelop esophagus + great vessels; fuses with foregut mesentery to form the posteromedial portions of the diaphragm by 8th week GA; lateral margins of diaphragm develop from muscles of the thoracic wall; the posterolaterally located pleuroperitoneal foramina (Bochdalek) close last
Incidence: 1: 2,200 3,000 livebirths (0.04%); M:F = 2:1; most common intrathoracic fetal anomaly

Delayed onset following group B streptococcal infection!

Etiology:

Classification (Wiseman):

I. herniation early during bronchial branching leading to severe bilateral pulmonary hypoplasia; uniformly fatal
II. herniation during distal bronchial branching leading to unilateral pulmonary hypoplasia; survival possible
III. herniation late in pregnancy with compression of otherwise normal lung; excellent prognosis
IV. postnatal herniation with compression of otherwise normal lung; excellent prognosis

Associated anomalies in 20% of liveborn and in 90% of stillborn fetuses:

Location: L:R = 5 9:1

Right-sided hernias are frequently fatal!

Herniated organs:

small bowel (90%), stomach (60%), large bowel (56%), spleen (54%), pancreas (24%), kidney (12%), adrenal gland, liver, gallbladder

OB-US (diagnosis possible by 18 weeks GA):

Cx: (1) Bilateral pulmonary hypoplasia

(2) Persistent fetal circulation (postsurgical pulmonary hypertension)

Prognosis: (1) Stillbirth (35 50%)

(2) Neonatal death (35%)

Indicators of poor prognosis:

large intrathoracic mass with marked mediastinal shift, IUGR, polyhydramnios, hydrops fetalis, detection <25 weeks MA, intrathoracic liver, dilated intrathoracic stomach, other malformations

Mortality: in 10% death before surgery;

40 50% operative mortality;

(a) stomach intrathoracic vs. intraabdominal = 60% vs. 6%

(b) polyhydramnios vs. normal amniotic fluid = 89% vs. 45%

DDx: congenital adenomatoid malformation, mediastinal cyst (bronchogenic, neurenteric, thymic)

Bochdalek hernia (85 90%)

Incidence: 1:2,200 12,500 livebirths
Location: left (80%), right (15%), bilateral (5%)

Herniated organs:

mnemonic: 4 B's

Morgagni Hernia (1 3 5%)

Incidence: 1:4,800 live births; M > F

Herniated organs:

Often associated with:

Age: children, adults
mnemonic: 4 M's
DDx on CXR: thymoma, teratoma, germ cell tumor, lymphoma, thyroid lesion, pericardial cyst, lymphangioma

Septum Transversum Defect

Hiatal Hernia

Eventration (5%)

Unilateral eventration may be associated with:

Bilateral eventration may be associated with:

Location: anteromedial on right, total involvement on left side; R:L = 5:1

Traumatic Diaphragmatic Hernia

Prevalence: 0.8 1.6% of all blunt trauma; 5% of all diaphragmatic hernias, but 90% of all strangulated diaphragmatic hernias

Etiology of traumatic rupture of diaphragm:

Location: 77 90 98% on left side; posterolateral portion of diaphragm medial to spleen in a radial orientation; medial central tendon with intrapericardial hernia (3.4%)
Size: most tears are >10 cm in length

Herniation of organs (32 58%) in order of frequency:

stomach, colon, small bowel, omentum, spleen, kidney, pancreas

CXR:

Cave: cephalad margin of bowel may simulate an elevated diaphragm (look for haustra)
N.B.: tube first dips below diaphragm (rent spares esophageal hiatus with gastroesophageal junction remaining in its normal position)

CT (61% sensitive, 87% specific):

Associated with: abdominal + pelvic injury in 90 94%

MR:

P.492

Associated injuries:

Reasons for diagnostic misses:

Cx: life-threatening strangulation of bowel/stomach occurs in majority

90% of strangulated hernias are traumatic!

Prognosis: 30% mortality in unrecognized cases
DDx: eventration; diaphragmatic paralysis; normal variant of acquired diaphragmatic discontinuity posteriorly related to congenital Bochdalek hernia (6 11%)

Emphysema

Prevalence: 1.65 million people in USA
Cause: imbalance in elastase-antielastase system (due to increase in elastase activity in smokers/ 1-antiprotease deficiency) causing proteolytic destruction of elastin resulting in alveolar wall destruction

CXR (moderately sensitive, highly specific):

HRCT:

Rx: lung volume reduction surgery

Centrilobular Emphysema

Path: normal + emphysematous alveolar spaces adjacent to each other
Histo: enlargement of respiratory bronchioles + destruction of centrilobular alveolar septa in the center of the secondary pulmonary lobule; CHARACTERISTICALLY surrounded by normal lung; distal alveoli spared; severity of destruction varies from lobule to lobule
Predisposed: smokers (in up to 50%), coal workers
Cause: excess protease with smoking (elastase is contained in neutrophils + macrophages found in abundance in lung of smokers)
Site: apical and posterior segments of upper lobe + superior segment of lower lobe (relatively greater ventilationperfusion ratio in upper lobes favors deposition of particulate matter and release of elastase in upper lungs)

CXR (80% sensitivity for moderate/severe stages):

HRCT:

Panacinar Emphysema

Path: uniform enlargement of acini from respiratory bronchioles to terminal alveoli (from center to periphery of secondary pulmonary lobule) secondary to destruction of lung distal to terminal bronchiole
Cause: autosomal recessive alpha-1 antitrypsin deficiency in 10 15% (proteolytic enzymes carried by leukocytes in blood gradually destroy lung unless inactivated by alpha-1 protease inhibitor)
Age: 6th-7th decade (3rd-4th decade in smokers)
Site: affects whole lung, but more severe at lung bases (due to greater blood flow)

CXR:

HRCT:

P.493

Paracicatricial Emphysema

Usual cause: granulomatous inflammation, organized pneumonia, pulmonary infarction
Path: no consistent relationship to any portion of secondary lobule/acinus; frequently associated with bronchiolectasis producing honeycomb lung

CXR (rarely detectable):

HRCT:

Paraseptal Emphysema

Path: predominant involvement of alveolar ducts + sacs
Site: characteristically within subpleural lung and adjacent to interlobular septa + vessels

CXR:

HRCT:

Cx: spontaneous pneumothorax; bullae formation

Empyema

Organism: S. aureus, gram-negative + anaerobic bacteria

Stage:

CT:

DDx: simple/complicated parapneumonic effusion (negative Gram + culture stain), malignant effusion after sclerotherapy, malignant invasion of chest wall, mesothelioma, pleural tuberculosis, reactive mesothelial hyperplasia, pleural effusion of rheumatoid disease

Eosinophilic pneumonia

Classification:

P.494

Maybe associated with: rheumatoid arthritis

M:F = 1:2

Acute Eosinophilic Pneumonia

Etiology: idiopathic (no evidence of infection/exposure to potential antigens) with abrupt increase in lung cytokines
Age: 32 17 years; M > F
Histo: eosinophilic infiltrates + pulmonary edema (from release of eosinophilic granules altering vascular permeability)
Rx: IV corticosteroids
Dx: bronchoscopy with bronchopulmonary lavage
DDx: chronic eosinophilic pneumonia (infiltrates with peripheral predominance)

Chronic Eosinophilic Pneumonia

Hypereosinophilic Syndrome

Cx: mitral + tricuspid insufficiency

Extrinsic Allergic Alveolitis

Cause: inhalation of organic dust (= particulate organism/protein complex) typically of 1 2 m (always <5 m) particle size deposited in distal airspaces of lung acting as antigen for a type III + type IV immune reaction
Histo: diffuse predominantly mononuclear cell inflammation of bronchioles (bronchiolitis) + pulmonary parenchyma (alveolitis); ill-defined granulomas of <1 mm in diameter
Location: predominantly midlung zones, occasionally lower lung zones, rarely upper lung zones

Specific antigens for immune complex disease (type III = Arthus reaction):

Thermophilic actinomycetes:

Isocyanates:

Rx: mask, filter, industrial hygiene, alterations in forced-air ventilatory system, change in patient's habits/occupation/environment

Acute Extrinsic Allergic Alveolitis

Histo: filling of air spaces by polymorph neutrophils + lymphocytes
Onset of symptoms: 4 8 hours after exposure
Dx: classical presentation of a known exposure history + typical symptoms + detection of serum precipitins to suspected antigen

Subacute Extrinsic Allergic Alveolitis

Histo: predominantly interstitial lymphocytic infiltrate, poorly defined granulomas, cellular bronchiolitis
Onset of symptoms after exposure: weeks months

Chronic Extrinsic Allergic Alveolitis

Onset of symptoms after exposure: months years
Histo: proliferation of epithelial cells + predominantly peribronchiolar interstitial fibrosis
Location: usually in mid zones, relative sparing of lung apices + costophrenic sulci

CT:

Fat Embolism

Incidence: in necropsy series in 67 97% of patients with major skeletal trauma; however, symptomatic fat embolism syndrome in <10% (M > F)
Onset: 24 72 hours after trauma

Focal Organizing Pneumonia

Prevalence: 5 10% of all pneumonias (87% of pneumonias resolve within 4 weeks, 12% within 4 8 weeks)
Predisposing factors: ? age, diabetes mellitus, chronic bronchitis, overuse of antibiotics
Histo: organization of intraalveolar exudate + thickening of alveolar septa/chronic inflammatory change of bronchial mucosa + obstructive lesion in bronchioles with organization

Fracture of Trachea/Bronchus

Cause: blunt chest trauma (in 1.5%)
Location: (a) mainstem bronchus within 2.5 cm of carina (80%); r > L

(b) just above carina (20%)

Prognosis: 30% mortality (in 15% within 1 hour)
Long-term Cx: airway stenosis/bronchomalacia; recurrent atelectasis/pneumonia

Giant Cell Interstitial Pneumonia

Goodpasture Syndrome

Pathogenesis:

Age peak: 26 years (range 17 78 years); M:F = 7:1
Prognosis: death within 3 years (average 6 months) because of renal failure
Rx: cytotoxic chemotherapy, plasmapheresis, bilateral nephrectomy
DDx: idiopathic pulmonary hemosiderosis

Granuloma of Lung

Cause:

Histo: epithelial cells, lymphocytes, macrophages, giant cells of Langhans type
Frequency: constitutes the majority of solitary pulmonary nodules
DDx: carcinoma (in 10% eccentric calcification in preexisting scar/nearby granuloma/true intrinsic stippled calcification in larger lesion)

Hamartoma of Chest Wall

Age: 1st year of life
Rx: resection curative

P.497

Hamartoma of Lung

Incidence: 0.25% in population (autopsy); 6 8% of all solitary pulmonary neoplasms; 77% of all benign lung tumors

Etiology:

Path: solitary mass composed of tissues normally found in this location in abnormal quantity, mixture, and arrangement
Histo: columnar, cuboidal, ciliated epithelium, fat (in 50%), bone, cartilage (predominates), muscle, vessels, fibrous tissue, calcifications, plasma cells originating in fibrous connective tissue beneath mucous membrane of bronchial wall
Age peak: 5th + 6th decade; M:F = 2:1 3:1

May be associated with:

Location: 2/3 peripheral; endobronchial in 3 10 20%; multiplicity (rare)
Transthoracic needle biopsy: 85% diagnostic accuracy
DDx: lipoid pneumonia (ill-defined mass/lung infiltrate); granulomatous disease, carcinoid tumor; metastatic mucinous adenocarcinoma, amyloidoma

Hereditary Hemorrhagic Telangiectasia

Etiology: gene that encodes transforming growth factor binding protein
Path: direct connections between arteries + veins with absence of capillaries (telangiectases are small AVMs)

(a) small telangiectasis = focal dilatation of postcapillary venules with prominent stress fibers in pericytes along luminal borders

(b) fully developed telangiectasis = markedly dilated + convoluted venules with excessive layers of smooth muscle without elastic fibers directly connecting to dilated arterioles

Cx: atypical cirrhosis, portal hypertension, variceal GI hemorrhage, ascites, encephalopathy
Cx: (1) congestive heart failure (due to AV shunting)

(2) cerebral abscess (from paradoxical emboli)

Histoplasmosis

Prevalence: nearly 100% in endemic area; up to 30% in Central + South America, Puerto Rico, West Africa, Southeast Asia; annually 500,000 infected in USA; up to 30% of US population has a positive skin reaction
Organism: Histoplasma capsulatum = dimorphic fungus; worldwide most often in temperate climates; widespread in soil enriched by bird droppings of central North America (endemic in Ohio, Mississippi, St. Lawrence River valley; exists as a spore in soil + transforms into yeast form at normal body temperatures
Vector: fowl + other birds (passes through feces without infection due to high body temperature); bats
Infection: inhalation of wind-borne spores (microconidia of 2 6 m, macroconidia of 6 14 m), which germinate within alveoli releasing yeast forms, which are phagocytized but not killed by macrophages; invasion of pulmonary lymphatics with spread to hilar + mediastinal lymph nodes; hematogenous dissemination of parasitized macrophages throughout reticuloendothelial system (spleen!)
Path: spores incite formation of epithelioid granulomas, necrosis, calcification
Dx: (1) Culture (sputum, lung tissue, urine, bone marrow, lymph node)

(2) Identification of yeast forms stained with PAS/Gomori methenamine silver

(3) Complement fixation test (absolute titer of 1:64 or 4-fold rise in convalescent titer suggest active/recent infection)

(4) Serum immunodiffusion: agar gel diffusion test (H precipitin band)

Rx: ketoconazole

P.498

Pulmonary Histoplasmosis

Hodgkin Disease

Incidence: 0.75% of all cancers diagnosed each year; 40% of all lymphomas
Age: bimodal peaks at age 25 30 years and 75 80 years
Histo: Reed-Sternberg cell = binucleate cell with prominent centrally located nucleolus

Ann Arbor Staging Classification:

Stage I = limited to one/two contiguous anatomic regions on same side of diaphragm
Stage II = >2 anatomic regions/two noncontiguous regions on same side of diaphragm
Stage III = on both sides of diaphragm, not extending beyond lymph nodes, spleen (Stage IIIS), Waldeyer's ring
IIIE = with extralymphatic organ/site
Stage IV = organ involvement (bone marrow, bone, lung, pleura, liver, kidney, GI tract, skin) lymph node involvement
E = extralymphatic site
S = splenic involvement
Substage A = absence of systemic symptoms
Substage B = fever, night sweats, pruritus, 10% weight loss in past 6 months

Extranodal Hodgkin Disease (15 30%)

CX: increased risk for other malignancies from aggressive therapy (acute leukemia, NHL, radiation-induced sarcoma)

Hydatid Disease

Source: hematogenous spread from liver lesion
Frequency: 15 25% of hydatid disease
Location: lower lobes in 60%; bilateral in 20%
CX: bacterial infection (after cyst rupture)

Hypogenetic Lung Syndrome

May be associated with:

Location: R:L = 3:1; RML (65%) > RUL (40%) > RLL (20%) > LUL (20%) > LLL (15%); multiple lobes (45%)

Horseshoe Lung

= uncommon variant of hypogenetic lung syndrome in which RLL crosses midline between esophagus and heart + fuses with opposite LLL

Idiopathic Interstitial Pneumonia

Acute interstitial Pneumonia

Path: temporally homogeneous organizing diffuse alveolar damage; little mature collagen deposition/architectural distortion/honeycombing (as opposed to UIP)

P.502

Histo:

Mean age: 50 years; M = F
Location: mainly lower lung zones
Site: predominantly central/subpleural (in 22%)
Dx: negative bacterial/viral/fungal cultures; no inhalational exposure to noxious agents; no pulmonary drug toxicity
Prognosis: death within 1 6 months (60 90%); recovery in 12%

Subacute Interstitial Pneumonia

BOOP see BRONCHIOLITIS OBLITERANS

Nonspecific Interstitial Pneumonia with Fibrosis

Histo: temporal uniformity of

Cause: collagen vascular disease (16%), inhalational exposure to noxious agents (17%), recent surgery/severe pneumonia/Ards (8%)
Mean age: 46 years; M < F
Location: no zonal predominance

HRCT:

Prognosis: 11% overall mortality
Rx: corticosteroids (clinical + functional + radiographic improvement in 50 86%)
DDx: usual interstitial pneumonia (irregular reticular pattern + honeycombing involving subpleural + lower lung zones

Respiratory Bronchiolitis-Interstitial Lung Disease

= interstitial pneumonia of smokers in which respiratory bronchiolitis is associated with limited peribronchiolar interstitial inflammation;? early manifestation of DIP

Mean age: 36 years; M = F
Cause: heavy cigarette smoking
Histo: accumulation of brown-pigmented macrophages in respiratory bronchioles + surrounding air spaces

CT:

Prognosis: excellent (after cessation of smoking/corticoid therapy) without progression to end-stage lung fibrosis

Chronic Interstitial Pneumonia

= ORGANIZING INTERSTITIAL PNEUMONIA = CHRONIC DIFFUSE SCLEROSING ALVEOLITIS

Usual Interstitial Pneumonia

Etiology: 50% idiopathic; 25% familial; drug exposure (bleomycin, cyclophosphamide (Cytoxan ), busulfan, nitrofurantoin); 20 30% associated with collagen vascular disease/immunologic disorder (mostly rheumatoid arthritis)
Pathophysiology: repetitive episodes of lung injury to the alveolar wall causing alveoli to flood with proteinaceous fluid + cellular debris; incomplete lysis of intraalveolar fibrin; type II pneumocytes regenerate over the intraalveolar collagen incorporating the fibrous tissue into alveolar septa (= injury-inflammation-fibrosis sequence)
Mean age: 64 years; M>F
Path: simultaneous presence of inflammatory cell infiltration + fibrotic alveolar walls + honeycombing + areas of normal lung tissue (= temporal variegation)
Histo: proteinaceous exudate in interstitium + hyaline membrane formation in alveoli; necrosis of alveolar lining cells followed by cellular infiltration of mono- and lymphocytes + regeneration of alveolar lining; intraalveolar histiocytes; proliferation of fibroblasts + deposition of collagen fibers + smooth muscle proliferation; progressive disorganization of pulmonary architecture

P.503

HRCT (88% sensitive):

Location: lung bases (68 80%)
Site: predominantly subpleural regions (79%)
Cx: bronchogenic carcinoma (more frequent occurrence)
Rx: response to steroids in only 10 15%
Prognosis: average survival of 3 6 years; 45% 5-year mortality rate (overall 87%); no recovery

Desquamative Interstitial Pneumonia

Mean age: 42 years (approximately 8 years younger than in UIP); M > F
Path: focal filling of alveolar spaces with foamy histiocytes + relative preservation of lung architecture + mild fibrosis (temporally uniform)
Histo: alveoli lined by large cuboidal cells + filled with heavy accumulation of mononuclear cells (macrophages, NOT desquamated alveolar cells); relative preservation of alveolar anatomy; histologic uniformity from field to field
Predisposed: smokers (history in up to 90%)

HRCT:

Location: mainly middle + lower lung zones (73%); bilateral + symmetric (86%)
Site: predominantly subpleural distribution (59%)
Prognosis: better response to corticosteroid Rx than UIP (in 60 80%); median survival of 12 years; 5% 5-year mortality rate (overall 16 27%);70% 10 year survival

Idiopathic Pulmonary Fibrosis

clinical syndrome

Age: 50 70 years; M > F

CXR:

HRCT:

Rx: corticosteroids, immunosuppressive/cytotoxic agents (<10% respond); lung transplantation
Prognosis: 30 50% 5-year survival

Idiopathic Pulmonary Hemosiderosis

IPH = probable autoimmune process with clinical + radiologic remissions + exacerbations characterized by eosinophilia + mastocytosis, immunoallergic reaction, pulmonary hemorrhage, iron deficiency anemia

Age:

Prognosis: death within 2 20 years (average survival 3 years)

DDx:SECONDARY PULMONARY HEMOSIDEROSIS

Inflammatory Myoblastic Pseudotumor

= PLASMA CELL GRANULOMA = INFLAMMATORY PSEUDOTUMOR = (FIBROUS) HISTIOCYTOMA = XANTHOMA

Prevalence: <1% of all tumors of lung + airways
Histo: composed of variable portions of plasma cells, lymphocytes, fibroblasts, blood vessels; foamy histiocytes + multinucleated giant cells + spindle cells (70% of tumor) grouped in CHARACTERISTIC pinwheel/whorled pattern
Age: young patient
Location: lung > bronchus/trachea > pleura
Rx: surgical excision

Kartagener Syndrome

= IMMOTILE/DYSMOTILE CILIA SYNDROME

Incidence: 1:40,00; high familial incidence
Etiology: abnormal mucociliary function secondary to generalized deficiency of dynein arms of cilia affecting respiratory epithelium, auditory epithelium, sperm

Triad:

Associated anomalies:

Klebsiella Pneumonia

Most common cause of gram-negative pneumonias; community acquired

Incidence: responsible for 5% of adult pneumonias
Organism: Friedl nder bacillus = encapsulated, nonmotile, gram-negative rod
Predisposed: elderly, debilitated, alcoholic, chronic lung disease, malignancy
Cx: meningitis, pericarditis
Prognosis: mortality rate 25 50%
DDx: Acute pneumococcal pneumonia (bulging of fissures, abscess + cavity formation, pleural effusion/empyema frequent)

Pulmonary Langerhans cell histiocytosis

Age: most frequently in 3rd 4th decade (range 3 months to 69 years); m:f = 4:1; caucasians > Blacks
Location: usually bilaterally symmetric, upper + mid lung predominance, sparing of bases + costophrenic angles

Evolutionary sequence on radiography:

DDx for nodules:

DDx for cysts:

DDx: sarcoidosis (equal sex distribution, always multisystem disease, not related to smoking, erythema nodosum, bilateral hilar lymphadenopathy, lung cavitation + pneumothorax rare, epithelioid cells)

Cx:

Prognosis: poor with multisystem disease + organ dysfunction (especially with skin lesions);

Mortality: 2 25%
Rx: cessation of smoking, chemotherapy (vincristine sulfate, prednisone, methotrexate,6-mercaptopurine)

Legionella Pneumonia

= LEGIONNAIRES' DISEASE

Organism: Legionella pneumophila, 1 2 m, aerobic, gram-negative bacillus, weakly acid-fast, silver-impregnation stain
Predisposed: middle-aged/elderly, immunosuppressed, alcoholism, chronic obstructive lung disease, diabetes, cancer, cardiovascular disease, chronic renal failure, transplant recipients
Transmission: direct inhalation (air conditioning systems)
Prevalence: 6% of community-acquired pneumonias
Histo: leukocytoclastic fibrinopurulent pneumonia with histiocytes in intraalveolar exudate

Clue: involvement of other organs with

Concomitant infection (in 5 10%):

Location: unilateral/bilateral (less frequent); lobar/segmental
Cx: progressive respiratory failure (most common cause of death; 6% mortality in healthy patients)
Rx: erythromycin

Lipoid Pneumonia

Acute Exogenous Lipoid Pneumonia

= FIRE-EATER PNEUMONIA

Material: liquid paraffin, petroleum (hydrocarbons)
Cause: accidental poisoning in children, fire-eaters

P.506

Chronic Exogenous Lipoid Pneumonia

Etiology: aspiration/inhalation of fatlike material

Types of oils:

Predisposed: elderly, debilitated, neuromuscular disease, swallowing abnormalities (eg, scleroderma)
Path: pool of oil emulsified by lung lipase + surrounded by giant cell foreign body reaction (mineral oil aspiration)/necrotizing hemorrhagic bronchopneumonia (higher content of free fatty acid in animal fat aspiration)
Histo: numerous lipid-laden macrophages distending alveolar walls + interstitium, accumulation of lipid material, inflammatory cellular infiltration, variable amount of fibrosis
Location: predilection for RML + lower lobes

CT:

Dx: bronchoalveolar lavage, transbronchial biopsy

L ffler Syndrome

Path: interstitial + alveolar edema containing a large number of lymphocytes
Prognosis: may undergo spontaneous remission

Lung Transplant

Indications for transplantation:

Unilateral lung transplants:

Contraindicated in: c ystic fibrosis, bronchiectasis (due to cross-contamination)
Operative mortality: up to 8%

Recurrence of primary disease:

Survival rate: 90% for 1 month, 84% for 3 month, 74% for 1 year, 58% for 3 years, 47% for 5 years, 24% for 10 years

Acute Rejection of Lung Transplant

Incidence: 60 80% with 2 3 significant episodes in first 3 months
Histo: mononuclear cell infiltrate around arteries, veins, bronchioles, alveolar septa with alveolar edema (initially) + fibrinous exudate (later)
Time of onset: first episode 5 10 days after transplantation; occasionally by 48 hours

Dx:

Rx: methylprednisolone, polyclonal T-cell antibody (antithymocyte globulin), monoclonal antibodies (CD3, OKT3), lymphoid irradiation

Anastomotic Complications of Lung Transplant

Chronic Rejection of Lung Transplant

= BRONCHIOLITIS OBLITERANS SYNDROME (BOS)

Prevalence: 24%

Risk factor: frequent/severe bouts of acute rejection, gastroesophageal reflux
Path: obliterative bronchiolitis (36%), interstitial pneumonitis, rejection-mediated vasculopathy
Time of onset: 3 75 months after transplantation

HRCT:

CXR:

Hyperacute Rejection of Lung Transplant

= rejection in cases of an immunoglobulin G donor-specific HLA antibody positive crossmatch

Path: acute diffuse alveolar damage

Posttransplantation Infection

Cause: immunosuppression, reduced mucociliary clearance, interruption of lymphatic drainage, direct contact of transplant with environment via airways
Incidence: 35 86% of transplant recipients

Posttransplantation Lymphoproliferative Disease

Incidence: 4 6%
Histo: spectrum from benign polyclonal B-cell proliferation of lymphoid tissue to aggressive monoclonal non-Hodgkin lymphoma
Associated with: Epstein-Barr virus
Time of onset: 1 month to several years; related to immunosuppressive regimen
Location: intrathoracic (most common in 1st year), extrathoracic (late development) in GI tract, skin, oropharynx, solid organs

Reperfusion Edema

Risk factors: poor organ preservation, prolonged ischemic time, unsuspected donor pathology (contusion, aspiration), interrupted lymphatic supply, cytokine-mediated injury
Pathogenesis: permeability edema due to lymphatic disruption, pulmonary denervation, organ ischemia, trauma
Histo: fluid accumulation in interstitium consistent with noncardiogenic pulmonary edema
Time course: manifests within 24 hours, peaks at 2nd-4th postoperative day, resolves at variable rate ranging from days to 1 2 weeks to months
Location: perihilar areas + basal regions in transplanted lung

P.508

Dx: per exclusion (radiographic changes not due to LV failure, hyperacute rejection, fluid overload, infection, atelectasis)
Prognosis: usually resolves over 7 to 10 days
Rx: diuresis, mechanical support

Lymphangiomyomatosis

Prevalence: 1:1,000,000
Etiology: unknown; hamartomatous proliferation of a particular form of HMB-45 positive smooth muscle (? forme fruste of tuberous sclerosis)
Age: 17 62 (mean, 34) years, exclusively in women of childbearing age
Path: hyperaerated lungs with extensive diffuse 5 20 mm cysts affecting both lungs + distorting pleural surfaces
Histo: abnormal proliferation of atypical smooth muscle cells (LAm cells) in pulmonary lymphatic vessels, blood vessels, and airways

Pathogenesis:

Hormonal influence: menstruation, pregnancy, exogenous estrogen treatment may result in exacerbation of symptoms

Cause of thin-walled lung cysts:

May be associated with: Tuberous sclerosis (lung involvement in 1%)

CXR:

CT:

NUC (V/Q scan):

P.509

DDx:

Lymphangitic Carcinomatosis

Incidence: 7% of all pulmonary metastases
Tumor origin: bronchogenic carcinoma, carcinoma of breast (56%), stomach (46%), thyroid, pancreas, larynx, cervix
mnemonic: Certain Cancers Spread By Plugging The Lymphatics

Path:

Location: bilateral; unilateral if secondary to lung primary

CXR (accuracy 23%):

HRCT:

Prognosis: death within 1 year

DDx:

Lymphoid Interstitial Pneumonia

Histo: extensive infiltration of bronchovascular bundles, interlobular septa, and pleura by polyclonal mature small lymphocytes + plasma cells; many cases reclassified as lymphoma
Associated with: Sj gren syndrome, autoimmune thyroid disease, AIDS, Castleman disease, systemic lupus erythematosus, myasthenia gravis, pernicious anemia, chronic active hepatitis

CT:

Prognosis:

P.510

Rx: responsive to steroids
DDx: Hypersensitivity pneumonitis (ground-glass attenuation, small centrilobular nodules, NOT cystic airspaces/thickening of interlobular septa or bronchovascular bundles)

Localized form = PSEUDOLYMPHOMA

Lymphoma

Pathogenesis: ? viral cause
Incidence: 3% of all newly diagnosed cancers; 3rd most common cancer in childhood (behind leukemia + CNS neoplasms); 4 times more common than Hodgkin disease
Predisposed: (40 100 times greater risk) congenital immunodeficiency syndromes, organ transplant patients undergoing immunosuppression, patients with HIV infection, collagen vascular diseases
Age: all ages; median age of 55 years; M:F = 1.4:1

Modified Rappaport Classification:

= categorization according to histologic distribution of lymphomatous cells

Luke and Collins Classification:

Working Formulation Classification (Kiel/Lennert):

Extranodal Involvement of NHL

Differences Between NHL and hodgkin Disease
Organ Involvement NHL HD
Thoracic involvement 45% 85%
Mediastinal nodes posterior anterior
Lung involvement 4% 12%
Lymphadenopathy
Periaortic adenopathy 49% 25%
Mesenteric adenopathy 51% 4%
Liver involvement 14% 8%
Hepatomegaly 57% <30%
Splenic involvement 41% 37%

Nodal involvement of NHL

Differences Between NHL and hodgkin Disease
Organ Involvement NHL HD
Thoracic involvement 45% 85%
    Mediastinal nodes posterior anterior
    Lung involvement 4% 12%
Lymphadenopathy
    Periaortic adenopathy 49% 25%
    Mesenteric adenopathy 51% 4%
Liver involvement 14% 8%
    Hepatomegaly 57% <30%
Splenic involvement 41% 37%
Comparison of Histologic Classifications of Non-Hodgkin Lymphoma
International Working Formulation Rappaport Classification
Low grade
     A. small lymphocytic Well-differentiated lymphocytic
     B. follicular, predominantly small cleaved cell Nodular, poorly differentiated lymphocytic
     C. follicular, mixed small and large cell Nodular, mixed
Intermediate grade
     D. Follicular, predominantly large cell Nodular, histiocytic
     E. Diffuse, small cleaved cell Diffuse, poorly differentiated lymphocytic
     F. Diffuse, mixed small and large cell Diffuse, mixed
     G. Diffuse, large cell, cleaved or noncleaved
High grade
     H. Diffuse large cell, immunoblastic
     I. Small, noncleaved cell
     J. Lymphoblastic Undifferentiated

Differences Between Nhl And Hodgkin Disease

HD: contiguous spread requires scanning of abnormal area only
NHL: noncontiguous spread requires scanning of chest, abdomen, pelvis
Differences between Adult and Childhood NHL
Characteristics Adult NHL Childhood NHL
Primary site nodal extranodal
Histology 50% follicular, 50% diffuse diffuse
Grade low, intermediate, high high
Histologic subtype many three
Sex predilection none 70% male

Non-Hodgkin Lymphoma in Childhood

Incidence: 3rd most common childhood malignancy (after leukemia + cns tumors); 7% of all malignancies in children <15 years of age
Origin: B or T cell (in 90%) located outside marrow; (rarely) non-B and non-T cells located within bone marrow
Age: median age of 10 years; <15 years of age (most common); unusual <5 years of age; m > f

Staging (St. Jude):

I single extranodal tumor/single anatomic area
II
  1. single extranodal tumor + regional nodes
  2. 2 nodal areas on same side of diaphragm
  3. 2 single extranodal tumors nodes on same side of diaphragm
  4. primary gastrointestinal tract tumor nodes

III
  1. 2 single extranodal tumors on opposite sides of diaphragm
  2. 2 nodal areas on both sides of the diaphragm
  3. primary intrathoracic tumors (mediastinum, pleura, thymus)
  4. extensive primary intraabdominal disease
  5. paraspinal/epidural tumor

IV any of the above + initial CNS/bone marrow involvement
Prognosis: 80% cure rate with multiple-agent chemotherapy
DDx:
  1. Acute lymphocytic leukemia (>25% lymphoblasts within bone marrow)
  2. Hodgkin disease (contiguous spread, nodes are site of origin)

P.512

Undifferentiated/Small Noncleaved NHL (39%)

Path: non-Burkitt lymphoma; Burkitt lymphoma
Primary site: abdomen (distal ileum, cecum, appendix); ovaries
Common site: mesenteric, inguinal, iliac nodes; CNS; bone marrow; kidney
Rare site: orbit, supradiaphragmatic paraspinal region, mediastinum, paranasal sinuses, bone, testes, pulmonary parenchyma
Cx: leukemic transformation (= extensive bone marrow involvement)

Lymphoblastic (T-cell) NHL (28%)

Primary site: mediastinum (66%)
Common site: neck, thymus, liver, spleen, CNS, bone marrow, gonads
Rare site: subdiaphragmatic (ileum, cecum, kidney, mesentery, retroperitoneum), orbit, paranasal sinus, thyroid, parotid

Large Cell (histiocytic) NHL (26%)

Origin: B cell, T cells (small percentage)
Location: nodal + extranodal
Primary site: variable (Waldeyer ring, Peyer patches)
Common site: peripheral lymph nodes, lung, bone, brain, skin
Rare site: hard palate, esophagus, trachea

Lymphomatoid Granulomatosis

Age: 7 85 (mean of 48) years; M:F = 2:1
Path: multiple sharply marginated masses adjacent to a bronchus causing obstructive pneumonitis
Histo: angiocentric infiltrate of atypical lymphoid cells (of B-cell lineage containing Epstein-Barr virus) with vascular invasion + destruction; necrotic lung parenchyma in higher grade lesions; giant cells absent (DDx to Wegener granulomatosis)
Cx: lymphoma (12 47%)
Mortality: in 53 90% from sepsis, respiratory failure, pulmonary embolism, massive hemoptysis, CNS lesions

Lymphoproliferative Disease After Transplantation

abnormal proliferation of lymphoid cells in immunocompromised organ transplant recipients in a spectrum ranging from mild lymphoid hyperplasia to malignant lymphoma

Incidence: 2% of all allograft recipients:

bone marrow transplantation 0.6%

renal graft transplantation 1 5%

cardiac transplantation 1.8 20%

liver transplantation 2%

lung transplantation 6.2 9.4%

Pathophysiology of B-cell (in 86%) origin:

Time of onset: 2 5 months (mean) after bone marrow, lung, heart-lung transplantation; 23 32 months (mean) after kidney, heart, liver transplantation

Under cyclosporine/OKT3 within 1 month

Unique features:

P.513

Meconium Aspiration Syndrome

most common cause of neonatal respiratory distress in full term/postmature infants (hyaline membrane disease most common cause in premature infants)

Etiology: fetal circulatory accidents/placental insufficiency/postmaturity result in perinatal hypoxia + fetal distress with meconium defecated in utero
Pathogenesis: severe hypoxemia induces gasping reflex with inhalation of tenacious meconium that produces medium and small airway obstruction + chemical pneumonitis
Incidence: 10% of all deliveries have meconium-stained amniotic fluid, 1% of all deliveries have respiratory distress
Rx: extracorporeal membrane oxygenation (major indication besides diaphragmatic hernia + neonatal pneumonia)
Cx: morbidity from anoxic brain damage is high

Mediastinal Lipomatosis

excess unencapsulated fat deposition

Etiology:

Location: upper mediastinum (common), cardiophrenic angles + paraspinal areas (less common)

OTHER FEATURES:

Mesothelioma

Benign Mesothelioma

= LOCALIZED FIBROUS MESOTHELIOMA = LOCALIZED FIBROUS TUMOR OF THE PLEURA = SOLITARY FIBROUS TUMOR OF PLEURA = BENIGN LOCALIZED MESOTHELIOMA = BENIGN PLEURAL FIBROMA = FIBROSING MESOTHELIOMA = PLEURAL FIBROMYXOMA

Incidence: <5% of all pleural tumors
Age: 3rd 8th decade; mean age of 50 60 years; M:F = 1:1
Path: usually solitary mass arising from visceral pleura in 80% + parietal pleura in 20%
Histo: tumor originates from submesothelial fibroblasts, lined by layer of mesothelial cells
  1. relatively acellular fibrous tissue
  2. rounded spindle-shaped densely packed cells
  3. resembling hemangiopericytoma of lung

Cx: malignant degeneration in 37%
DDx: metastatic deposit
Rx: excision is curative (recurrence rate lower for pedunculated versus nodular tumor)

Malignant Mesothelioma

Prevalence: 7 13:1,000,000 persons/year; 2,000 3,000 cases/year in USA
Etiology: asbestos exposure (13 100%); zeolite (nonasbestos mineral fiber); chronic inflammation (TB, empyema); irradiation

P.514

Latency period: 20 35 45 years (earlier than asbestosis; later than asbestos-related lung cancer)
Peak age: 50 70 years (66%); M:F = 2 4 6:1
Path: multiple tumor masses involving predominantly the parietal pleura + to a lesser degree the visceral pleura; progression to thick sheetlike/confluent masses resulting in lung encasement
Histo: (a) epithelioid (60%), (b) sarcomatoid (15%), (c) biphasic (25%); intracellular asbestos fibers in 25%
Associated with: peritoneal mesothelioma; hypertrophic osteoarthropathy (10%)

Staging (Boutin modification of Butchart staging):

IA confined to ipsilateral parietal/diaphragmatic pleura
IB + visceral pleura, lung, pericardium
II invasion of chest wall/mediastinum (esophagus, heart, contralateral pleura) or metastases to thoracic lymph nodes
III penetration of diaphragm with peritoneal involvement or metastases to extrathoracic lymph nodes
IV distant hematogenous metastases
Stage at presentation: II in 50%, III in 28%, IV in 4%

Spread:

Prognosis: 10% of occupationally exposed individuals die of mesothelioma (in 50% pleural + in 50% peritoneal mesothelioma); mean survival time of 5 11 months
DDx: pleural fibrosis from infection (TB, fungal, actinomycosis), fibrothorax, empyema, metastatic adenocarcinoma (differentiation impossible)
Dx: video-assisted thoracoscopic surgery (postprocedural radiation therapy of all entry ports for tumor seeding of needle track [21%])

Metastasis to Lung

Pulmonary metastases occur in 30% of all malignancies; mostly hematogenous

Age: >50 years (in 87%)

Incidence of pulmonary metastases:

mnemonic: CHEST
Frequency of Pulmonary Metastases
Origin of pulmonary mets Probability of pulmonary mets
Breast 22% for Kidney cancer 75%
Kidney 11% for osteosarcoma 75%
Head and neck 10% for choriocarcinoma 75%
Colorectal 9% for Thyroid cancer 65%
Uterus 6% for melanoma 60%
Pancreas 5% for Breast cancer 55%
Ovary 5% for Prostate cancer 40%
Prostate 4% for Head and neck cA 30%
Stomach 4% for esophagus cA 20%

Solitary Metastatic Lung Nodule

Calcifying Lung Metastases (<1%)

mnemonic: BOTTOM
+ others: synovial sarcoma, giant cell tumor of bone, lung metastases following radiation/chemotherapy

Cavitating Lung Metastases

Frequency: 4% (compared with 9% in primary bronchogenic carcinoma)
Histo: squamous cell carcinoma (10%), adenocarcinoma (9.5%)
mnemonic: Squamous Cell Metastases Tend to Cavitate

Hemorrhagic Lung Metastases

CT:

Endobronchial Metastasis

Frequency: 1%

Lung Metastases in Childhood

mnemonic: ROWE

Metastases with Airspace Pattern

Sterilized Metastasis

= persistence of metastatic nodule without significant change in size after adequate chemotherapy

Histo: necrotic nodule fibrosis without viable tumor cells

Metastasis of Benign Tumor to Lung

Metastasis to Pleura

P.516

Mycoplasma Pneumonia

Incidence: 10 33% of all pneumonias; autumn peak
Organism: Eaton agent = pleuropneumonia-like organism (PPLO) = 350 m long pleomorphic Mycoplasma pneumoniae with lack of cell wall
Spread: direct contact/aerosol
Age: most common between 5 20 years (esp. in closed populations
Histo: peribronchial mononuclear cell infiltrates (similar to viral lower respiratory infection)
Rx: erythromycin, azithromycin, tetracycline
Cx: ? as an autoimmune response

  1. Acute disseminated encephalomyelitis
  2. Cerebral arteriovenous occlusion
  3. Erythema nodosum, erythema multiforme, Stevens-Johnson syndrome
  4. pulmonary: Swyer-James syndrome, pulmonary fibrosis, bronchiolitis obliterans, ARDS

Prognosis: 20% with recurrent symptoms of pharyngitis + bronchitis infiltrations
DDx: viral infection of lower respiratory tract, pertussis, chlamydia (indistinguishable)

Near Drowning

asphyxiation due to water inhalation followed by survival for a minimum of 24 hours

Stage 1:

Prognosis: resolution within 24 48 hours (under therapy)

Stage 2:

= laryngospasm + swallowing of water into the stomach

Stage 3:

Cx: ARDS, aspiration of gastric fluid, infection by fresh-water saprophytic bacteria

Similarities of all 4 types:

Cx: pneumonia (due to aspirated bacteria/fungi /mycobacteria)

Necrotizing Sarcoid Granulomatosis

Etiology: ? variant of sarcoidosis
Age: 3rd 7th decade (mean age, 49 years); M:F = 1:2.2
Path: pleural + subpleural + peribronchovascular scattered nodules/conglomerate masses central cavitation
Histo: confluent noncaseating granulomas, extensive necrosis, vasculitis of muscular pulmonary arteries + veins with frequently total vascular occlusion, bronchiolar obstruction, bronchiolitis obliterans, obstructive pneumonitis
Rx: corticosteroid therapy alone
DDx: sarcoidosis (high prevalence of mediastinal + hilar lymphadenopathy, little propensity for cavitation)

Neonatal Pneumonia

Pathogenesis:

Organism:

others: H. influenzae, Staphylococcus aureus, E. coli, CMV, pneumocystis

Nocardiosis

Organism: gram-positive acid-fast bacterium resembling fungus
Predisposed: immunocompromised

Nontuberculous Mycobacterial Infection Of Lung

Atypical Tuberculosis

Organism:

M. kansasii: lung infection in subjects with good immune status
M. marinum: swimming pool granuloma
M. ulcerans: Buruli ulcer in tropical areas
M. scrofulaceum: cervical lymphadenitis in infants
m. avium intracellulare: esp. in Aids

Organism causing pulmonary disease (Runyon classification): ubiquitous organisms as part of normal environmental flora

Histo: lesions indistinguishable from m. tuberculosis
Source: soil, water, dairy products, bird droppings
Infection: inhalation of aerosolized water droplets (M.avium-intracellulare complex), food aspiration in patients with achalasia (M. fortuitum-chelonei), GI tract (in AIDS)
DDx: M. tuberculosis (bronchiectasis less common + less extensive), bronchiolitis obliterans, sarcoidosis, fungal disease

Panbronchiolitis

inflammatory lung disease, prevalent in Orientals but rare in Europeans + North Americans

Pathogenesis: unknown

HRCT:

DDx: bronchiolitis obliterans

Paragonimiasis Of Lung

Infection: ingestion of raw/incompletely cooked freshwater crab/crayfish infected with metacercaria; larva exists in small intestine + penetrates the intestinal wall + enters peritoneal cavity; larva penetrates diaphragm + pleura to enter the lung
Cycle: from the final host (tiger, cat, dog, fox, weasel, opossum, human) eggs of worm pass to the outside with blood-streaked sputum; in fresh water ciliated embryos (miracidia) develop; they become tailed larvae (cercariae) after invading a fresh-water snail; when the infected snail is eaten by a crustacean, their tails detach and they become 300 m encysted larvae (metacercariae)
DDx: tuberculosis (nodular slowly changing lesion, residual fibrosis after treatment, no subpleural linear opacities)

Pericardial Cyst

Etiology:

Histo: lined by single layer of mesothelial cells
Age: 30 40 years; M:F = 3:2
Location:
  1. (a) cardiophrenic angle (75%), R:L = 3:1/3:2, 25% higher; may extend into major fissure
  2. (b) mediastinum (rare)

Pneumatocele

Developmental theories:

P.519

Pneumatocele Associated with Infection

Organism: pneumococci, E. coli, Klebsiella, Staphylococcus (in childhood)

Traumatic Pneumatocele = Pneumatocyst

Cause:

Pulverized Lung

Cause:severe chest trauma

Pneumococcal Pneumonia

Most common gram-positive pneumonia

90% community-acquired, 10% nosocomial

Incidence: 15% of all adulthood pneumonias, uncommon in child; peaks in winter + early spring; increased during influenza epidemics
Organism: Streptococcus pneumoniae (formerly Diplococcus pneumoniae), gram-positive, in pairs/chains, encapsulated, capsular polysaccharide responsible for virulence + serotyping
Susceptible: elderly, debilitated, alcoholics, CHF, COPD, multiple myeloma, hypogammaglobulinemia, functional/surgical asplenia
Location: usually involves one lobe only; bias for lower lobes + posterior segments of upper lobes (bacteria flow under gravitational influence to most dependent portions as in aspiration)

Variations (modified by bronchopulmonary disease, eg, chronic bronchitis, emphysema):

Prognosis: prompt response to antibiotics (if without complications); 5% mortality rate
Dx: blood culture (positive in 30%)
Cx: meningitis, endocarditis, septic arthritis, empyema (now rarely seen)

Pneumocystosis

Pneumonectomy Chest

Early signs (within 24 hours):

Late signs (after 2 months):

N.B.: Depression of diaphragm/shift of mediastinum to contralateral side indicates a bronchopleural fistula/empyema/hemorrhage!

Postobstructive Pneumonia

chronic inflammatory disease distal to bronchial obstruction

Cause:

Histo:

Progressive Massive Fibrosis

Path: avascular amorphous central mass of insoluble proteins stabilized by cross-links + ill-defined bundles of coarse hyalinized collagen at periphery
Location: almost exclusively restricted to posterior segment of upper lobe/superior segment of lower lobe

Pseudolymphoma

= reactive benign lesion = localized form of lymphocytic interstitial pneumonitis (LIP); no progression to lymphoma

Histo: aggregates of plasma cells, reticulin cells, large + small lymphocytes with preserved lymphoid architecture resembling lymphoma histologically without lymph node involvement
Associated with: sj gren syndrome
Prognosis: occasionally progression to non-Hodgkin lymphoma
Rx: most patients respond well to steroids initially

Pseudomonas Pneumonia

Organism: Pseudomonas aeruginosa, gram-negative

Pulmonary Arterial Malformation

Etiology:

Path: hemangioma of cavernous type

Pathophysiology:

Age: 3rd 4th decade; manifest in adult life, 10% in childhood

Occurrence:

Types:

Location: lower lobes (65 70%) > middle lobe > upper lobes; bilateral (8 20%); medial third of lung

CT (98% detection rate):

MR (if contraindication to contrast material/if flow slow due to partial thrombosis/for follow-up):

Angio (mostly obviated by MR/CT unless surgery or embolization contemplated):

Cx: CNS symptoms are commonly the initial manifestation

Prognosis: 26% morbidity, 11% mortality
Recommendation: screening of first-degree relatives
DDx: solitary/multiple pulmonary nodules
Rx: embolization with coils/detachable balloons

Pulmonary capillary hemangiomatosis

bilateral pulmonary disease behaving like a low-grade nonmetastatic vascular neoplasm with slowly progressive pulmonary hypertension

Histo: sheets of thin-walled capillary blood vessels infiltrating pulmonary interstitium + invading pulmonary vessels, bronchioles, and pleura

Pathomechanism of pulmonary hypertension:

Age: 20 40 years

CXR:

P.522

CT:

Angio:

Prognosis: death after 2 12-year interval from onset of symptoms
Rx: bilateral lung transplantation

DDx:

Pulmonary contusion

most common manifestation of blunt chest trauma, esp. deceleration trauma

Path: exudation of edema + blood into airspace + interstitium
Time of onset: apparent within 6 hours after trauma
Location: posterior (in 60%)
Site: directly deep to site of impact/contrecoup

CT:

Cx: pneumothorax
DDx: fat embolism (1 2 days after injury)

Pulmonary Infarction

ischemic coagulative necrosis of lung parenchyma

Frequency: rare (due to protective effect of collateral blood flow from bronchial circulation)
Path: dark necrotic material (with faint ghostlike structures of lung tissue remaining evident on histology) sur-rounded by a narrow rim of hyperemia + inflammation
Cause: pulmonary artery occlusion (medium- to small-sized vessel)

Pathogenesis:

Co-condition to progress to infarction:

Prognosis: replacement by vascular fibrous tissue folding into a collagenous platelike mass producing pleural retraction

Pulmonary Interstitial Emphysema

PIE = complication of respirator therapy with PEEP

Pathogenesis:

Cx:

Rx:  
DDx:
  1. high-frequency jet/oscillatory ventilation
  2. placing affected side of infant down for 24 48 hours
  3. selective bronchial intubation

Pulmonary Lymphangiomatosis

Pulmonary Mainline Granulomatosis

Drugs: amphetamines, methylphenidate hydrochloride ( West coast ), tripelen amine ( blue velvet ), methadone hydrochloride, dilaudid, meperidine, pentazocine, propylhexedrine, hydromorphone hydrochloride
Pathogenesis: talc (= magnesium silicate) particles incite a pronounced granulomatous foreign-body reaction + subsequent fibrosis in perivascular distribution
Path: multiple scattered whitish nodules of 0.3 3 mm converging into gritty fibrotic masses in central + upper lungs measuring several cm
Histo: widespread granulomas packed with doubly refractile talc particles expanding the walls of muscular pulmonary arteries and arterioles + perivascular connective tissue + alveolar septa

P.523

Early changes:

Late changes:

Cx: mycotic pulmonary artery aneurysm; right-sided endocarditis with septic emboli; chronic respiratory failure; emphysema; systemic talc breakthrough to liver + spleen + kidneys + retina

DDx of late changes:

Dx: lung biopsy
Clinical Classification of Pulmonary Thromboembolic disease according to Severity
Signs & Symptoms Class 1 Class 2 Class 3 Class 4
occlusion of pulmonary arteries <20% 20 30%% 30 50% >50%
symptoms asymptomatic anxiety, hyperventilation dyspnea, collapse shock, dyspnea
Arterial Po2 normal <80 torr <65 torr <50 torr
Arterial Pco2 normal <35 torr <30 torr <30 torr
central venous pessure normal normal elevated elevated
mean PA pressure normal >20 mm Hg
systolic blood pressure normal <100 mm Hg

Pulmonary Thromboembolic Disease

= PULMONARY EMBOLISM (PE)

Incidence: 600,000 Americans/year (0.23%) with missed/delayed diagnosis in 400,000, causing death in 100,000; diagnosed in 1% of all hospitalized patients; in 12 64% at autopsy; in 9 56% of patients with deep venous thrombosis
Age: 60% >60 years of age
Cause: deep vein thrombosis (DVT) of extremities/pelvis (>90%), right atrial neoplasia/thrombus, thrombogenic intravenous catheters, endocarditis of tricuspid/pulmonic valves
Time of onset: PE usually occurs within first 5 7 days of thrombus formation

Predisposing factors:

Pathophysiology: A clot from the deep veins of the leg breaks off + fragments in right side of heart + showers lung with emboli varying in size
Location of PE: bilateral emboli (in 45%), R lung only (36%), L lung only (18%); multiple emboli [3 6 on average] in 65%
Distribution: RUL (16%), RML (9%), RLL (25%), LUL (14%), LLL (26%)
Site: central = segmental/larger (in 58%); peripheral = subsegmental/smaller (in 42%); in subsegmental branches exclusively (in 30%)

Acute Pulmonary Thromboembolism

CXR (33% sensitive, 59% specific):

NECT (purpose):

CECT angio (method of choice):

N.B.: In the adult a CT (2.2 6.0 mSv) has a 1.6 4.3 times higher radiation dose than a V/Q scan (1.4 mSv)!
N.B.: evaluate the vessel adjacent to a bronchus

Pseudo-filling defects:

Technical failure rate: 3 4% due to severe dyspnea

NUC (V/Q scan = guide for angiographic evaluation) interpreted in reference to Biello or PIOPED criteria:

N.B.: In the fetus a V/Q scan (640 800 mSv) has a 5 267 times higher radiation dose than CT scan (3 131 mSv)!
N.B.: V/Q abnormalities vary over time due to autoregulation (hypoxic vasoconstriction, hypercapneic bronchoconstriction) and resolution

P.525

Angio (>95% sensitive + specific):

Indication:

Technique: AP & ipsilateral posterior oblique projection

Risks in pulmonary angiography:

Cx of pulmonary angiography (1 2%):

Mortality rate of pulmonary angiography: 0.2 0.5%

False-negative rate:

Rx:

Chronic Pulmonary Thromboembolism

= CHRONIC THROMBOEMBOLIC DISEASE

Frequency: 1 5% of patients with acute pulmonary thromboembolism, especially in patients with large emboli/recurrent episodes
At risk: underlying malignancy, cardiovascular disease, pulmonary disease; M < F
Path: fibrous webs and bands (= organized thromboemboli), often with overlying recent thrombosis; embolic material is incorporated into vessel wall + covered over by a thin layer of endothelial cells

Pathogenesis:

CXR:

CT (77% sensitive):

MR (lowest sensitivity):

Disadvantage: slow flow in central vessels may obscure embolic fixed signal

NUC:

Angio (highest specificity):

Prognosis: 30% 5-year survival with a mean PA pressure of 30 mm Hg
RX: thrombendarterectomy (7 40% operative mortality); supplemental warfarin anticoagulation therapy vasodilators

Tumor Embolism

CXR:

CT:

CECT:

NUC:

Angio:

Cx: subacute cor pulmonale (heralds death within 4 12 weeks)

Mercury Embolism

Cause: accidental/suicidal IV injection
Pathomechanism: intravascular mercury becomes encased in thrombus or migrates into pulmonary interstitium/alveolar spaces resulting in significant granulomatous response

Pulmonary Venous Varix

Etiology: congenital/associated with pulmonary venous hypertension
Location: medial third of either lung below hila close to left atrium
Risk:
  1. death upon rupture during worsening heart failure
  2. source of cerebral emboli

DDx: pulmonary arteriovenous fistula

Radiation Pneumonitis

Time of onset: usually 4 6 months after treatment
Location: confined to radiation portals

Respiratory Distress Syndrome Of Newborn

Frequency: 6:1,000 neonates (in 2002); M:F = 1.8:1
Cause: relative lack of mature type II pneumocytes causes deficiency of endogenous surfactant (production usually begins at 18 20 weeks of gestational age) which leads to increased alveolar surface tension + decreased alveolar distensibility causing acinar atelectasis (persistent collapse of alveoli) + dilatation of terminal airways
Histo: uniformly collapsed alveoli + variable distension of alveolar ducts + terminal bronchioles; lined by fibrin ( hyaline membranes ) 2 to protein seepage from damaged hypoxic capillaries
Predisposed: perinatal asphyxia, maternal/fetal hemorrhage, term infants of diabetic mothers, multiple gestations, premature infants (<1,000 g in 66%; 1,000 g in 50%; 1,500 g in 16%; 2,000 g in 5%; 2,500 g in 1%)
Onset: <2 5 hours after birth, increasing in severity from 24 to 48 hours, gradual improvement after 48 72 hours
Prognosis: spontaneous clearing within 7 10 days (mild course in untreated survivors); death in 18%
Rx:
  1. Antenatal maternal corticosteroid therapy
  2. Surfactant replacement therapy (liquid bolus of exogenous surfactant delivered into tracheobronchial tree
  3. Nasal continuous positive airway pressure (CPAP)
  4. High-frequency oscillatory ventilation (HFOV)
  5. Extracorporeal membrane oxygenation (ECMO)

DDx:
  1. Diffuse pneumonia accompanying sepsis
  2. Retained fetal lung fluid (first few hours)
  3. Pulmonary hemorrhage
  4. Pulmonary venous congestion (eg, TAPVR, pulmonary vein atresia, hypoplastic left heart)
  5. Premature with accelerated lung maturity (PALM baby)

Causes of Asymmetric Clearing after Surfactant

Acute & Subacute Complications of RDS

Chronic Complications of RDS

Complication of Continuous Positive Pressure Ventilation (CPAP)

Cause: airway overdistension (volutrauma) rather than high airway pressure (barotrauma)

Path:

Rx: mechanical ventilatory assistance with positive end-expiratory pressure (to increase oxygen diffusion)

Retained Fetal Lung Fluid

Incidence: 6%; most common cause of respiratory distress in newborn
Cause: cesarean section, precipitous delivery, breech delivery, prematurity, maternal diabetes

Pathophysiology:

Onset: within 6 hours of life; peaks at 1st day of life
Prognosis: resolving within 1 2 4 days (retrospective Dx)
DDx:
  1. Normal (during first several hours of life)
  2. Diffuse pneumonitis/sepsis
  3. Mild meconium aspiration syndrome
  4. Alveolar phase of RDS
  5. Drowned newborn syndrome = clear amniotic fluid aspiration
  6. Pulmonary venous congestion (eg, left heart failure, overhydration, placental transfusion)
  7. Pulmonary hemorrhage
  8. Hyperviscosity syndrome = thick blood
  9. Immature lung syndrome = premature with accelerated lung maturity (PALM baby)

Rheumatoid Lung

Prevalence: 2 54% of patients with rheumatoid arthritis; M:F = 5:1 (although incidence of rheumatoid arthritis: M < F)
Stage 1: multifocal ill-defined alveolar infiltrates
Stage 2: fine interstitial reticulations (histio- and lymphocytes)
Stage 3: honeycombing

Round Pneumonia

Organism: Haemophilus influenzae, Streptococcus, Pneumococcus
Age: children >> adults
Location: always posterior, usually in lower lobes

Sarcoidosis

Prevalence: 10 40:100,000 in USA
Age peak: 20 40 years; m:f = 1:3 (more common in women + people of West African descent); American Blacks:American Whites = 10:1 (rare in African/south American Blacks); more common in blood group A
Histo: alveolitis (earliest changes); noncaseating epithelioid granulomas [composed of lymphocytes, peripheral fibroblasts, multinucleated giant cells] with occasional minimal central necrosis
Location: along course of lymphatic vessels: subpleural, septal, perivascular, peribronchial
DDx: indistinguishable from granulomas of berylliosis, treated TB, leprosy, fungal disease, hypersensitivity pneumonitis, crohn disease, primary biliary cirrhosis

P.530

Dx: based on a combination of clinical + radiological + histologic features after exclusion of other infectious/inflammatory entities

Clinical Forms:

Stage at presentation:

0 normal chest radiograph 5%
I hilar + mediastinal lymphadenopathy only 50%
II lymphadenopathy + parenchymal disease 30%
III diffuse parenchymal disease only 15%
IV pulmonary fibrosis 20%

Prognosis:

80% spontaneous remission of stage 1 + 2 disease
75% complete resolution of hilar adenopathy
33% complete resolution of parenchymal disease
30% improve significantly
20% irreversible pulmonary fibrosis (may persist unchanged for >15 years)
5% mortality (cor pulmonale/CNS/lung fibrosis/liver cirrhosis)
25% relapse (in 50% detected by CXR)

Abdominal Sarcoidosis

Bone Sarcoidosis (6 15 20%)

Gastrointestinal Sarcoidosis

Location: anywhere from esophagus to rectum

Genitourinary Sarcoidosis (0.2 5%)

Skin Sarcoidosis (10 30%)

P.531

Thoracic Sarcoidosis (90%)

Associated with: tuberculosis in up to 13%
Site: predominantly mid-zone + upper lung involvement

HRCT:

Atypical manifestations (25%):

Cx:
  1. pneumothorax secondary to chronic lung fibrosis (rare)
  2. cardiomegaly from cor pulmonale (rare)
  3. aspergilloma formation in apical bulla (in >50% of stage IV disease)

Diagnostic criteria:

Assessment of activity:

Sarcoidosis of Other Organs

Septic Pulmonary Emboli

Organism: S. aureus, Streptococcus
Predisposed: IV drug abusers, alcoholism, immunodeficiency, CHD, dermal infection (cellulitis, carbuncles)

Source:

Age: <40 years
Location: predilection for lung bases

P.532

Cx: empyema (39%)

Siderosis

= inert iron oxide/metallic iron deposits

Path: iron phagocytized by macrophages in alveoli/respiratory bronchioles, elimination from lung by lymphatic circulation

Occupational exposure:

DDx: silicosis (nodular opacities more dense + profuse)

Silicosis

= inhalation of silicon dioxide; most prevalent silicosis of progressive nature after termination of exposure; similar to CWP (because of silica component in CWP)

Substance: crystalline silica (quartz); one of the most widespread elements on earth

Occupational exposure:

Dust deposition: dependent on
Path: small particles engulfed by macrophages; liberation of silica results in cell death; 2 3-mm nodules with layers of laminated connective tissue around smaller vessels
Cx: predisposes to tuberculosis
DDx: coal worker pneumoconiosis (identical radiographs)

Acute Silicosis

Histo: proliferation of type II pneumatocytes + profuse surfactant production
Exposure time: as short as 6 8 months
Associated with: increased risk to develop autoimmune disease
Distribution: lung periphery; predominantly lower lung zones; bilateral
Cx: infection with TB + atypical mycobacteria
Prognosis: often rapidly progressive with death from respiratory failure
DDx: alveolar proteinosis

Chronic Simple Silicosis

At least 10 20 years of dust exposure before appearance of roentgenographic abnormality

Location: upper + posterior lung zones

Complicated Silicosis

Location: midzone/periphery of upper lung migrating toward hila
Distribution: often bilateral symmetric + nonsegmental

Silicotuberculosis

Caplan Syndrome

more common in coal worker's pneumoconiosis

Staphylococcal Pneumonia

Organism: staphylococcus aureus = gram-positive, appears in clusters, coagulase-producing

Streptococcal Pneumonia

Incidence: 1 5% of bacterial pneumonias (rarely seen); most common in winter months
Organism: Group A -hemolytic streptococcus

= Streptococcus pyogenes, gram-positive cocci appearing in chains

Predisposed: newborns, following infection with measles
Associated with: delayed onset of diaphragmatic hernia (in newborns)
Cx: (1) Residual pleural thickening (15%)

(2) Bronchiectasis

(3) Lung abscess

(4) Glomerulonephritis

Swyer-James Syndrome

Etiology: acute viral bronchiolitis in infancy/early childhood (adenovirus, RSV) preventing normal development of lung
Path: variant of postinfectious constrictive bronchiolitis with acute obliterative bronchiolitis, bronchiectasis, distal airspace destruction (developing in 7 30 months)
Location: one/both lungs (usually entire lung, occasionally lobar/subsegmental)
DDx: no air trapping with proximal interruption of pulmonary artery (no hilum), hypogenetic lung syndrome, pulmonary embolus
DDx: pulmonary artery atresia (uncommon in adults), localized bullous emphysema (deviation of vessels), bronchial obstruction

Systemic Lupus Erythematosus

Prevalence: 1:2,000; Blacks:Caucasians = 3:1; increased risk in relatives
Cause: local deposition of antigen-antibody complexes/antibodies inducing necrotizing vasculitis (type III immune complex phenomenon) of the small blood vessels
Age: 16 41 years; M:F = 1:10 (women of childbearing age)
Prognosis: 60 90% 10-year survival; death from renal failure/sepsis/CNS involvement/myocardial infarction

Drug-induced Lupus Erythematosus (DIL)

Agents: procainamide, hydralazine, isoniazid, phenytoin account for 90%

Gastrointestinal SLE (in up to 50%)

Renal SLE

Prevalence: kidneys involved in 100% with renal disease developing in 30 50%
Histo: focal membranoproliferative glomerulonephritis

US:

CT:

Cx: (1) Nephrotic syndrome (common)

(2) Renal vein thrombosis (in 33%)

Prognosis: end-stage renal disease is common cause of death

Skin SLE (81%)

Thoracic SLE (30 70%)

Talcosis

Teratoid Tumor Of Mediastinum

P.535

Pathogenesis: misplaced multipotential primitive germ cells during migration from yolk endoderm to gonad

Incidence:

Classes: (1) Mature teratoma (solid)

(2) Cystic teratoma (dermoid cyst)

(3) Immature teratoma

(4) Malignant teratoma (teratocarcinoma)

(5) Mixed teratoma

Location: mediastinum is 3rd most common site for teratoid lesions (after gonadal + sacrococcygeal location); 5% of all teratomas occur in mediastinum, mostly anterosuperiorly (in only 1% posteriorly)
Cx:
  1. Hemorrhage
  2. Pneumothorax (from bronchial obstruction with air trapping + alveolar rupture)
  3. Respiratory distress (rapid increase in size from fluid production) with compression of trachea/SVC (SVC syndrome)
  4. Fistula formation to aorta, SVC, esophagus
  5. Rupture into bronchus (expectoration of oily substance/trichoptysis in 5 14%, lipoid pneumonia)
  6. Rupture into pericardium (pericardial effusion), pleural cavity (pleural effusion)

DDx: thymoma

Benign Teratoid Tumor (75 86%)

Path: spherical lobulated well-encapsulated tumor; typically multi-/unilocular cystic cavities with clear/yellow/brown liquid

Histo:

Age: young adults/children; M = F

Location:

Prognosis: approx. 100% 5-year survival rate
Rx: complete surgical excision

Malignant Teratoid Tumor (14 20%)

Histo: similar to mature teratoma but with primitive/immature tissue elements; commonly neural tissue arranged in rosettes/primitive tubules

Thoracic Paraganglioma

Age: 3rd 5th decade; m:f = 1:1
Path: extremely vascular well-marginated/irregular mass that may adhere to/envelop/invade adjacent mediastinal structures (bronchus, spinal canal)
Histo: anastomosing cords of granule-storing chief cells arranged in a trabecular pattern; identical appearance for benign and malignant tumors

May be associated with:

Location: base of heart + great vessels (adjacent to pericardium/heart, within interatrial septum/left atrial wall); paravertebral sulci

CT:

MR:

NUC (I-123/I-131 metaiodobenzylguanidine):

Angio (may precipitate cardiovascular crisis):

Rx: surgical excision with preoperative administration of - or -blockers (hypertensive crisis, tachycardia, dysrhythmia during manipulation)

Thymic Cyst

Pathogenesis:

Incidence: very uncommon lesion; 1 2% of mediastinal masses
Age: 2/3 in 1st decade; 1/3 in 2nd + 3rd decades; M>F
Path: unilocular thin-walled cyst with thymic tissue
Histo: squamous/cuboidal/respiratory epithelium in cyst wall; lobulated lymphoid tissue in cyst wall containing Hassall corpuscles; cholesterol crystals; small foci of thyroid/parathyroid tissue

Location:

US:

DDx: branchial cleft cysts (no thymic tissue), benign thymoma, teratoma, dermoid cyst, Hodgkin disease, non-Hodgkin lymphoma, pleural fibroma

Thymic Hyperplasia

Age: particularly in young individual

Histo:

Etiology:

DDx: thymic neoplasm (focal mass)

Thymolipoma

Incidence: 2 9% of thymic tumors
Age: 3 60 years (mean age of 22 years); M:F = 1:1
Path: lobulated pliable encapsulated tumor capable of growing to large size (in 68% >500 g, in 20% >2,000 g, the largest >16 kg)
Histo: benign adult adipose tissue interspersed with areas of normal/hyperplastic/atrophic thymus tissue (thymic tissue <33% of tumor mass)
DDx: mediastinal lipoma (most common of intrathoracic fatty tumors), liposarcoma
WHo Classification for Thymic Epithelial Tumors
Tumor Type Description
A medullary
AB mixed
B1 lymphocyte rich, predominantly cortical
B2 cortical
B3 epithelial = well-differentiated thymic carcinoma
C thymic carcinoma

Thymoma

Age: majority >40 years; 70% occur in 5th 6th decade; less frequent in young adults, rare in children; M:F = 1:1
Associated with: parathymic syndromes (40%) such as
Path: round/ovoid slow-growing primary epithelial neoplasm with smooth/lobulated surface divided into lobules by fibrous septa; areas of hemorrhage + necrosis may form cysts

Histo:

Location: any anterior mediastinal location between thoracic inlet and cardiophrenic angle; rare in neck, other mediastinal compartments, lung parenchyma, or tracheobronchial tree
Size: 1 10 cm (up to 34 cm)

Noninvasive [Benign] Thymoma

Age peak: 5th 6th decade, almost all are >25 years of age

CT:

MRI:

Invasive [Malignant] Thymoma

Frequency: in 30 35% of thymomas
DDx: malignant mesothelioma, lymphoma, thymic carcinoma/malignant germ cell tumor (older male, no diffuse pleural seeding), peripheral lung carcinoma (no dominant mediastinal mass), metastatic disease (not unilateral)
Rx: radical excision adjuvant radiation therapy
Prognosis: 5-year survival of 93% for stage I, 86% for stage II, 70% for stage III, 50% for stage IV; 2 12% rate of recurrence for resected encapsulated thymomas

Torsion of Lung

Incidence: rare (<30 cases)
Age: almost invariably in children
Cause: compression of lower thorax, tear on inferior pulmonary ligament, completeness of fissures
Mechanism: compression of lower thorax with lung twisted through 180 ; usually in presence of a large amount of pleural air/fluid
Associated with: surgery (lobectomy), trauma, diaphragmatic hernia, pneumonia, pneumothorax, bronchus-obstructing tumor
Histo: hemorrhagic infarction + excessive air trapping

Tracheobronchomegaly

Incidence: 0.5 1.5%
Age: discovered in 3rd 5th decade
May be associated with: Ehlers-Danlos syndrome

Tracheobronchopathia Osteochondroplastica

Cause: unknown; may be due to chronic inflammation, degenerative process, irritation by oxygen/chemical, metabolic disturbance, amyloidosis, tuberculosis, syphilis, heredity (high prevalence in finland)

P.539

Pathogenetic theories:

Path: foci of submucosal hyaline cartilage with areas of lamellar bone
Histo: adipose tissue + calcified areas with foci of bone marrow; thinned normal overlying mucosa with inflammation + hemorrhage
Average age: 50 years (11 78 years); m:f = 3:1
Location: distal 2/3 of trachea, larynx, lobar/segmental bronchi, entire length of trachea; spares posterior membrane of trachea

CXR:

CT:

Dx: bronchoscopy
DDx: relapsing polychondritis, tracheobronchial amyloidosis (does not spare posterior membranous wall of trachea),

Traumatic Lung Cyst

Age: children + young adults are particularly prone

Tuberculosis

Prevalence: 10 million people worldwide, active TB develops in 5 10% of those exposed
Organism: mycobacterium = acid-fast aerobic rods staining red with carbol-fuchsin; m. tuberculosis (95%), atypical types increasing: m. avium-intracellulare, m. kansasii, m. fortuitum
Susceptible: infants, pubertal adolescents, elderly, alcoholics, Blacks, diabetics, silicosis, measles, Aids (30 40% infected with HIV), sarcoidosis (in up to 13%)
At risk: immunocompromised, minorities, poor, alcoholics, immigrants from 3rd world countries, prisoners, the aged, nursing home residents, homeless

Pathologic phases:

Spread: regional lymph nodes, hematogenous dissemination, pleura, pericardium, upper lumbar vertebrae
Former Rx: plombage with insertion of plastic packs, Lucite balls, polythene spheres; oleothorax = injection of oil/paraffin
Mortality: 1:100,000

Tuberculoma

Cavitary Tuberculosis

Cx:

Endobronchial (Acinar) Tuberculosis

Path: ulceration of bronchial mucosa followed by fibrosis leads to

(a) bronchial stenosis (lobar consolidation)

(b) bronchiectasis

(c) acinar nodules reflecting airway spread

HRCT:

Primary Pulmonary Tuberculosis

Mode of infection: inhalation of infected airborne droplets
Age: most common form in infants + childhood; increasingly encountered in adults (23 34% of all adult cases)
Location: middle lobe, lower lobes, anterior segment of upper lobes
DDx: varicella pneumonia, histoplasmosis, metastases, sarcoidosis, pneumoconiosis, hemosiderosis
DDx of Lnn: metastases, histoplasmosis

CT:

Outcome of primary infection:

Prognosis: 3.6% mortality rate
Cx: (1) Bronchopleural fistula + empyema

(2) Fibrosing mediastinitis

Postprimary Pulmonary Tuberculosis

Incidence: 1% per year in persons with normal immunity, up to 10% in persons with deficient T-cell immunity
Age: predominantly in adolescence + adulthood

Etiology:

Path: foci of caseous necrosis with surrounding edema, hemorrhage, mononuclear cell infiltration; formation of tubercles = accumulation of epithelioid cells + Langhans giant cells; bronchial perforation leads to intrabronchial dissemination (19 21%)
Site: 85% in apical + posterior segments of upper lobe, 10% in superior segment of lower lobe, 5% in mixed locations (anterior + contiguous segments of upper lobe); R > L (DDx: histoplasmosis tends to affect anterior segment)

Local Exudative Tuberculosis

CT:

Local Fibroproductive Tuberculosis

Miliary Pulmonary Tuberculosis

Cause:

Incidence: 2 3.5% of TB infections
Cx: dissemination via bloodstream affecting lymph nodes, liver, spleen, skeleton, kidneys, adrenals, prostate, seminal vesicles, epididymis, fallopian tubes, endometrium, meninges

Unilateral Pulmonary Agenesis

Varicella-Zoster Pneumonia

Incidence: 14% overall; 50% in hospitalized adults
Age: >19 years (90%); 3rd 5th decade (75%); contrasts with low incidence of varicella in this age group
Cx: unilateral diaphragmatic paralysis
Prognosis: 11% mortality rate

Wegener Granulomatosis

Path: peribronchial necrotizing granulomas + vasculitis not intimately related to arteries
Mean age of onset: 40 years (range of all ages);M:F = 2:1

CLASSIC TRIAD:

Limited Wegener Granulomatosis

Dx: c-ANCA (96% sensitive, 99% specific)

M < F

Prognosis: more favorable than classical Wegener's

Midline Granuloma

Williams-Campbell Syndrome

Wilson-Mikity Syndrome

Prognosis: resolution over 12 months
DDx: perinatally-acquired infection (especially CMV)

Zygomycosis

Organism: ubiquitous Mucor (most common), Rhizopus, Absidia with broad nonseptated hyphae of irregular branching pattern
At risk: immunoincompetent host with 1. lymphoproliferative malignancies and leukemia

2. acidotic diabetes mellitus

3. immunosuppression through steroids, antibiotics immunosuppressive drugs (rare)

Entry: inhalation/aspiration from sinonasal colonization
Path: angioinvasive behavior similar to aspergillosis
Dx: culture of fungus from biopsy specimen/demonstration within pathologic material
DDx: aspergillosis

Категории